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ABSTRACT 
 
This thesis summaries three years of research on the development of innovative porous silica 
based devices for biosensing and drug delivery purposes. Porous silicon (PSi), is one of most 
exploited nanostructured material in biomedicine. Due to its optical and electrical properties, 
high specific surface area, tailorable morphology and surface chemistry, PSi is an ideal 
transducer material for the realization of high sensitive and selective biosensors. In this work, 
different porous silica structures have been explored for the development of label-free 
oligonucleotide-biosensor realized by in situ synthesis of bioprobe on porous platform. 
Different functionalization strategies have been also explored in order to make PSi surface 
more chemically stable. The realization of label-free aptamer-PSi sensor, with great stability, 
fast response time, high sensitivity and specificity for the detection of human α-thrombin, has 
been successfully demonstrated. Diatomite, an emerging natural porous silica material of 
sedimentary origin, with similar physiochemical properties of man-made porous silicon, has 
been also exploited as potential platform for biomedical applications. Its non-toxicity, 
biocompatibility, high specific surface area, tailorable surface chemistry, as well as thermal 
and chemical stability make diatomite a viable cheap surrogate to synthetic porous silica for 
realization of nano-based drug delivery system. In this thesis work the potentialities of 
diatomite nanoparticles (DNPs) as safe nanovectors for drug delivery in cancer cells have 
been successfully demonstrated. Since the silica surface of diatomite is covered by silanol 
groups, it can be easily modified with functional reactive groups for the conjugation of 
biomolecules (e.g., DNA, antibodies, enzymes) in order to realize advanced healthcare 
devices. Different approaches of functionalization based on covalent bond for preparation of 
bioengineered diatomite NPs for therapeutic molecules transport into cancer cells were 
developed. Preliminary in vitro and in vivo studies endorsed this cheap, natural and 
biocompatible nanomaterial for drug delivery applications.  
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1 INTRODUCTION 
1.1 Nanostructured porous silicon based devices for biomedical applications 
Nanotechnology has allowed the development of innovative nanostructured materials 
characterized by enhanced properties with respect to their correspondent bulk materials. In 
recent years, nanomaterials have been used for a wide range of applications, including 
electronics, medicine, food, pharmaceutics, energy production, consumer products, and so on 
[1–3]. Application of nanostructured materials in biomedicine offers several advantages 
compared to traditional materials, due to the possibility to radically change and tune their 
physicochemical properties [4]. For example, the porosification of materials at the nanoscale 
results in the enhancement of their biochemical properties such as bioactivity, 
biocompatibility, avoiding the triggering of immune responses and inflammatory processes 
into human body, typical of bulk materials [5]. Over the last decades, several types of organic, 
inorganic and natural materials have been used for biomedical applications. One of these that 
has highly impacted biomedical field is porous silicon (PSi) [6]. PSi obtained by 
electrochemical etching of doped crystalline silicon, is one of the most exploited synthetic 
nanostructured material due to its peculiar properties [5, 6]. Morphology, pore size and 
surface chemistry can be easily changed and controlled, making it a very versatile material 
[7]. Due to its optical and electrical properties, and to its sponge-like morphology 
characterized by a high specific surface area, PSi has been largely used in fabrication of 
innovative biosensors [8–11]. Moreover, thermal stability, chemical inertness, 
biocompatibility, high loading capability, adaptable dissolution kinetic, made this material 
suitable for development of nanodevices for drug delivery applications [5, 12, 13]. In recent 
years, emerging natural porous materials have also been suggested to overcome the 
shortcomings of synthetic porous materials, finding in diatomite one of the most outstanding 
surrogate [14]. Diatomite, also known as diatomaceous earth, is a fossil material of 
sedimentary origin formed over centuries by siliceous skeleton (called “frustule”) of aquatic 
unicellular microalgae diatoms, with similar physicochemical properties of man-made 
fabricated PSi [15, 16]. The unique properties of this inexpensive material have found 
application in several fields including optics, photonics, sensing, biosensing, filtration, 
immunoprecipitation, microfluidics, catalysis and nanofabrication [17–21]. Due to ordered 
pore structure, high surface area, tailorable surface chemistry, high permeability, 
biocompatibility, non-toxicity, low cost, low density, optical and photonic properties, 
diatomite has been exploited as an innovative platform in several biotechnological 
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applications resulting as a viable and promising cheap alternative to synthetic porous silica 
[14, 22, 23]. 
1.2 Synthetic oligonucleotides for bioengineering of nanostructured devices  
Surface modification of nanostructured devices with biomolecules (i.e., bioengineering) is 
one of the most challenging and fastest growing component of nanotechnology, which 
transforms inert materials in advanced ones for medical purpose. [24]. Among different 
biomolecules used for this function (i.e., enzymes, proteins, antibodies, peptides) DNA and its 
derivatives, are considered suitable as construction materials in nanoscience due to their 
peculiar properties [25]. DNA is a double stranded helical molecule, that can be separated into 
single-stranded DNA (ssDNA) units complementary to one other. When these ssDNA 
structures are brought together, they form again the duplex structure. Despite its simplicity, 
the enormous specificity of the adenine–thymine (A–T) and guanine–cytosine (G–C) 
Watson–Crick hydrogen bonding allows the development of high selective bioprobes for the 
development of specific DNA-devices. The power of DNA as a molecular tool is enhanced by 
the ability to synthesize DNA sequences with peculiar properties by automated methods [26]. 
Engineered synthetic nucleic acids, different from the canonical DNA can fold into various 
other secondary structures such as G-quadruplexes [27]. G-quadruplexes are unusual nucleic 
acids that can form within specific repetitive G rich DNA or RNA sequences, characterized 
by the stacking of units (G-tetrads), consisting of four guanines organized in a square planar 
arrangement. Each guanine is linked to the two adjacent ones by Hoogsteen hydrogen bonds, 
involving the amino and imino protons and the nitrogen N7 and oxygen O6 atoms (Figure 
1.1). Many reports suggest that G-quadruplex structures have important applications in 
several and different areas, ranging from medicinal chemistry to the nanotechnologies [28, 
29]. An interesting property of G-quadruplex structures is that they may serve as scaffold of 
aptamers. Aptamers are an emerged class of single-stranded RNA or DNA oligonucleotides 
able to fold into well specific three-dimensional (3D) structures, generated from SELEX 
technique [30, 31]. This process relying on DNA or RNA libraries allows automatic synthesis 
of a large variety of nucleic acid sequences with great selectivity for non-nucleic acids 
molecules. In contrast to other nucleic acid molecules, aptamers are able to interact with their 
targets through a structural recognition similar to an antibody-antigen reaction with 
dissociation constant in the range of pico- to nano-molar, thus referred to as chemical 
antibodies [32]. 
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Fig. 1.1. Graphical representation of a G-tetrad and a G-quadruplex. 
 
However, different from antibodies, the chemical nature of nucleic acids allows easy 
synthesis and various feasible ways to engineer aptamers with extended bioavailability, 
regulating ability, and multi-functional properties. Aptamers can be easily obtained by 
automatic synthesis with good reproducibility contrary to antibodies which are obtained by in 
vivo immunization of animals. [30–32]. Aptamers are thermally stable, even after a 95 °C 
denaturation they can refold into their correct 3D conformation once cooled to room 
temperature, unlike protein-based antibodies which permanently lose their activity at high 
temperatures [30]. The targets of aptamers range from small molecules, to proteins, virus-
infected cells, stem cells, and cancer cells. Chemical features and biological functions have 
made aptamers a very attractive tool in biomedical applications ranging from bioassays to 
targeted therapy. Moreover, aptamer technology has shown a great potential for 
bioengineering of nanostructured devices. In the past few years, integration of functional 
aptamers into nanomaterials has become a new interdisciplinary field that aims at providing 
new hybrid sensing systems for specific and sensitive molecular recognition [33, 34]. 
Aptamer used as bioprobe for the development of biosensor, opened new generation of DNA 
biosensors called aptasensors [35]. Due to their unique properties, aptamers hold many 
advantages over antibodies, which have been widely used as recognition elements in 
biosensing. To date, aptamer-based biosensors have successfully detected a large number of 
analytes of interest, including small organic molecules, metal ions, and proteins, by taking 
advantages of the highly selective interactions of the aptamer with the target analytes and high 
signals amplification by the unique optical, electrical, and magnetic properties of various 
sensing platform used [35]. This novel integration, highlighted the potentiality of aptamers as 
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emerging tools for fabrication of new sensing devices for selective and sensitive detection of a 
wide range of analytes with great advances in healthcare applications. 
1.3 Porous silica optical biosensors for human disease diagnosis 
A growing need for small, fast, efficient and portable devices able to detect a specific analyte 
has meant biosensing one of the most rapidly expanding research field, ranging from a broad 
of applications including clinical diagnostics, environmental monitoring, veterinary and food 
quality control. A biosensor is an hybrid device constituted by a biomolecular probe, 
employed to selectively recognize a biochemical target, immobilized on a transducer surface 
which converts the target recognition into an analytical signal [36–38]. The porous silicon 
(PSi) obtained by electrochemical partial dissolution of doped crystalline silicon,
 
is by far one 
of the most intriguing optical transducer for developing of a wide variety of chemical and 
biological sensors [6, 7]. The potential application of the PSi structures to molecular 
screening for biomedical applications has gained widespread attention of scientific 
community, as demonstrated by several papers which proved the potentiality of PSi-based 
biosensors to detect analytes in heterogeneous mixture and in low concentrations [39]. PSi 
biosensors are label-free devices relying on electrical, electrochemical and optical 
mechanisms [40–42]. Optical biosensors are the most prevalent PSi biosensors, characterized 
by very short analysis time and high sensitivity. Moreover, opto-instruments used for 
measurements are non-invasive and safe also in harsh conditions such as in vivo monitoring 
inside a patient body where, for example, electrical-based devices could be harmful [43]. The 
label-free sensing mechanism of PSi optical structures is based on the change of their 
refractive index on exposure to the substances to be detected, due to their infiltration in the 
pores and air replacement. The consequence of the refractive index variation is a change in 
the reflectivity spectrum of the device (Figure 1.2). The selectivity of PSi device is obtained 
by a proper chemical surface functionalization (i.e., covalent immobilization) with 
biomolecular probes able to detect the target molecule from a complex mixture. The 
achievement of PSi as biosensor depends on the stability of its surface chemistry. 
Unfortunately, the freshly prepared hydrogen terminated (Si–H) PSi structures suffer 
instability in ambient air and aqueous solutions due to an uncontrolled oxidation of the 
surface [44]. The uncontrolled oxidation of PSi is a major problem in biosensor development, 
due to the continuous change in the refractive index of device which falsifies the signal 
transduction [45]. Many thermal and chemical strategies have been developed to stabilize PSi, 
thus preserving its optical properties for biosensing. 
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Fig. 1.2. Scheme of label-free sensing mechanism of PSi optical biosensor. 
 
Once passivated the PSi surface, the functionalization with biomolecular probes can be 
achieved, thus realizing a specific biosensor. Chapter 2, based on preliminary studies for the 
development of DNA-PSi biosensor by in situ solid phase oligonucleotides (ON) synthesis, 
describes the fabrication process, passivation and characterization of mesoporous silicon 
based oligonucleotide sensor. Since the chemistry used for the solid phase synthesis and 
deprotection of ON is quite aggressive for the PSi supports, the surface was stabilized by a 
thermal oxidation followed by a silanization. The in situ synthesis of single-stranded 
polythymine ON bioprobe, has been used as strategy to biofunctionalize the transducer’s 
surface. The advantages of in situ synthesis with respect to conventional ex situ 
immobilization are not only the increasing of DNA probe density but also the process 
automation, and the possibility of surface local functionalization [43]. Finally, the ON 
deprotection and label-free optical detection of DNA-DNA hybridization with a 
complementary ON sequence have been demonstrated, thus opening the prospective for the 
development of more specific DNA-PSi biosensors through solid phase synthesis without any 
restriction on the ON sequence composition and limitation of PSi surface stability. The 
development of a PSi aptasensor by in situ synthesis of anti-thrombin aptamer (TBA) 
bioprobe for label-free optical detection of human thrombin, is described in Chapter 3. The 
TBA is a well characterized chair-like antiparallel quadruplex structure that specifically binds 
the thrombin. Thrombin, a serine protease, plays important role in the coagulation cascade, 
thrombosis and haemostasis. The high nanomolar range of thrombin in blood was known to 
be associated with diseases, therefore, it is important to assess this protein at trace level with 
high sensitivity. TBA aptamer has been synthetized in macroporous (pore size ˃ 50 nm) 
amino-modified PSi structure which allowed a correct synthesis of the macroprobe with 
proper yield, with respect to mesoporous (10 ˂ pore size ˂ 50 nm) one. Further, it was proved 
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the stability, selectivity, reversibility and low limit of detection of PSi-aptasensor, resulting as 
a promising device for vascular diseases early diagnosis. 
1.4 Diatomite as natural porous silica material for drug delivery  
The application of nanotechnology in medicine for human disease diagnosis, treatment, and 
control of biological systems has been referred to as nanomedicine [46, 47]. This new 
emerging research field, paving the way for medical innovations, seeks to deliver a valuable 
set of research tools and clinically helpful nanostructured devices for human health [48, 49]. 
During the last decades, great efforts have been made in the development of innovative drug 
delivery systems, thus overcoming the drawbacks of conventional drug therapies [50−52]. 
Nanoparticle (NP)-based drug delivery systems have provided many advantages over 
conventional drug formulations such as selective drugs delivery to pathological sites, 
enhanced solubility of poorly-water soluble drugs, improved pharmacokinetics and short half-
lives of degradable molecules (e.g., peptides, proteins, DNA), simultaneous delivery of drugs 
for combination therapy to reduce the drug resistance. Despite the vast assortment of 
nanomaterials to develop nanocarriers, porous silicon/silica based devices are the most used 
drug delivery platforms due to the remarkable properties of this material. The most popular 
example among them are synthetic mesoporous silica-NPs (MPS-NPs) [53−55]. Due to 
excellent biocompatibility, high surface area, thermal stability, chemical inertness and 
diffusion controlled drug-release mechanism, MPS has been considered an ideal material for 
drug delivery applications [5, 6, 53–55]. However, the synthesis of MPS-NPs is time-
consuming and costly, involving high-energy consumption and toxic materials [56]. 
Therefore, to address some of these disadvantages, it was suggested to explore alternative 
natural porous silica materials for drug-delivery applications [14, 23]. The cheap fossil 
compound diatomite appears to be the most outstanding example of 3D structures biologically 
derived porous silica, given by Mother Nature, as shown in Figure 1.3. Diatomite possesses a 
combination of structural, mechanical and chemical features that can overcome challenges 
associated with conventional delivery of therapeutic agents and offer several advantages over 
existing synthetic delivery systems [14, 15]. Although, due to its peculiar properties diatomite 
is surprisingly still scarcely used in nanomedicine. In Chapter 4, the realization of silica-based 
nanoparticles from diatomite powder and the exploration of their potentialities as nanovectors 
for drug delivery in cancer cells are described. A purification procedure based on thermal 
treatments in strong acid solutions to make diatomite safer material for medical applications, 
fabrication techniques to reduce the micrometric diatomite powder to nanoparticles (DNPs), 
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Fig. 1.3. Frustules from some different diatom algae species. 
morphological and chemical characterization of the nanomaterial, as well as preliminary tests 
of cytotoxicity and cellular uptake, are presented in detail. Since the silica surface of 
diatomite is covered by silanol (SiOH) groups, it can be easily modified with functional 
reactive groups (−NH2, −COOH, −SH, −CHO) for the conjugation of biomolecules (e.g., 
DNA, antibodies, enzyme) in order to prepare bioengineered devices. In Chapter 5, different 
functionalization procedures for the preparation of biofunctionalized DNPs as non-toxic 
carriers for transport through cellular membranes of therapeutic molecules (i.e., small 
interfering RNA and  sorafenib) and the results on the effective enhancement of the DNPs’ 
physicochemical properties, biocompatibility and cellular uptake, are described. In Chapter 6, 
a preliminary in vivo toxicity study of diatomite NPs was evaluated by using Hydra vulgaris 
as new simple in vivo model.  
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2 OLIGONUCLEOTIDES-MODIFIED POROUS SILICA OPTICAL 
DEVICES FOR LABEL-FREE BIOSENSING 
 
(Papers J1, J2, P1) 
Significant efforts are being devoted to the development of more efficient DNA chip 
technology for applications in areas of social interest, such as gene expression analysis, 
medical diagnostics, and human therapies [1]. Commercial DNA chips use probes or targets 
labelled with chromophores or radioisotopes where the molecular recognition events (i.e., the 
hybridization of probes with targets) are monitored by fluorescence microscopes. Even if the 
fluorescence based technique is a standard in genomic applications, this method is strongly 
dependent on the labelling procedures, which sometimes can give undesirable effects on the 
molecular interactions [2, 3]. Moreover, reading and quantifying hundreds of thousands of 
fluorescence spots in a single run is not straightforward nor always precise. To overcome 
these limitations, a new class of label-free DNA chip has been proposed, which uses direct 
electrical or optical detection methods [4–6]. The label-free optical PSi devices promise to 
offer sensitivity, selectivity, and low cost method for the detection of DNA hybridization [7]. 
DNA chips can be classified as a special class of biosensors since they are realized by 
immobilization of single stranded oligonucleotide (ON) bioprobe, on a transducer surface. 
Each molecular interaction between the bioprobe and its ligand, such as hybridization to the 
complementary DNA sequence, is then transduced into an analytical signal by an 
electrochemical-, optical-, surface plasmon resonance-based or electrical device, depending 
on the specific technology used. Porous silicon (PSi) is by far one of the most popular 
transducer material due to its peculiar physical and chemical properties [8]. PSi is fabricated 
by electrochemical etching of crystalline silicon in aqueous hydrofluoric acid. Depending on 
etch time, current density and acid concentration, several porous morphologies can be 
obtained, from micropores (average pores size < 5 nm) to macropores (average pores size > 
50 nm) [9]. The resulting sponge-like matrix is characterized by a very large specific surface 
area (up to 300 m
2
/cm
2
). Even if electrochemical etching induces silicon dissolution, the PSi 
surface results smooth enough to get very good quality optical devices, also in the case of 
multilayered structures [10]. Periodic, or quasi-periodic, alternation of high and low porosity 
layers is used for fabrication of Bragg reflectors, microcavities, Thue-Morse sequences: all 
these photonic devices exhibit resonance wavelengths that can be used as monitoring peak in 
quantifying biomolecular interaction from the optical point of view [11–13]. Unfortunately, 
the PSi structures suffer instability from oxidation and corrosion in aqueous solutions, 
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especially simulating biological conditions. Lots of chemical protocols have been reported in 
literature in order to passivate and functionalize surfaces. The immobilization of biological 
species should not prevent their functions, and thus should also assure their correct 
organization and orientation. PSi surface can be properly functionalised in order to covalently 
bind biological molecules such as single or double stranded DNA, proteins, enzymes, 
antibodies, aptamers and so on, which act as bioprobes. There are many routes to achieve 
surface functionalization which are based on proper chemical or biological processes. PSi 
surface can be activated by specific chemical groups, namely –SH, –NH2 or –COOH, that 
could form very stable bonds, such as sulphide or peptide bond, with the biological molecule 
considered [14]. For some biomolecules that are usually synthesized ex situ and then coupled 
on PSi surface, there is also the possibility of directly growing the molecules (i.e., in situ 
synthesis) using PSi as support in the so-called solid phase synthesis [13, 15]. In this chapter, 
the realization of label-free DNA-PSi devices by in situ ON synthesis, is described. Since the 
chemistry used for the solid phase synthesis of ON can be quite aggressive against the PSi 
solid support, chemical stability of PSi supports is a key issue for the biosensor realization. In 
particular, it is well known that PSi suffers on exposure to alkaline solutions (commonly used 
for the deprotection of ON) which easily corrode the silicon skeleton; so a trade-off between 
PSi surface passivation and suitable solid-phase synthesis chemistry is strictly required. The 
fabrication, passivation and functionalization of PSi devices by using two different siloxanes, 
a comparison of their effectiveness for in situ ON synthesis and hybridization with 
complementary ON sequence, are described in detail.  
2.1 Porous silicon fabrication by electrochemical etching  
PSi is a very versatile material due to its peculiar morphological, physical, and chemical 
properties: evidence of this is the huge number of papers about PSi features and devices based 
on this nanostructured material, that appear in the literature every year [16–19]. One reason 
for this clear success is the easy fabrication of sophisticated optical multilayers by a simple, 
but not trivial, computer-controlled electrochemical etching process. The PSi structure is 
formed by electrochemical dissolution of doped crystalline silicon wafers in hydrofluoric acid 
(HF) based solution. The cell used for the electrochemical etching is schematized in Figure 
2.1. The silicon wafer is the anode; it is placed in back-side contact on an aluminum plate 
while the front side is sealed with an O-ring and exposed to the anodising electrolyte. The 
cathode is made of platinum. The anodisation cell is made of a highly-acid resistant polymer 
such as polyvinylidene fluoride (PVDF) or polytetrafluoroethylene (PTFE). 
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Figure 2.1. Electrochemical etching setup. 
 
 
 
Fig. 2.2. Anodic I-V curve for silicon in HF. In the region A pore formation occurs. In region 
C there is the silicon electropolishing. The region B is a transition zone where pore formation 
and electropolishing compete [19]. 
 
For highly resistive silicon substrate (> few mΩ/cm) an evaporated metal backside contact is 
necessary to ensure the Schottky contact between the aluminum plate and the semiconductor.  
Figure 2.2 shows the anodic I-V curve of cristaline silicon (n- or p-type) in HF based solution; 
the different dissolution regions of the curve are labeled A-C. Pore formation takes place in 
region A. At anodic overpotentials in excess of the current “peak,” region C, silicon 
electropolishes. At intermediate overpotentials, region B, a “transition” zone exists where 
pore formation and electropolishing compete for control over the surface morphology. The 
resulting structure within this region is generally porous in nature but the pore diameters 
increase rapidly as the electropolishing potential is approached. The exact dissolution 
chemistries of silicon are still in question, although it is generally accepted that holes are 
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required in the initial steps for both electropolishing and pore formation [19]. The Figure 2.3 
illustrates the chemical dissolution mechanism suggested by Lehmann and Gösele, that has 
received great attention [17]. If a hole of the silicon substrate has the sufficient energy to 
reach the surface, a nucleophilic attack on Si–H bond by fluoride ion can occur and a Si–F 
bond is formed (step 1 in Figure 2.3). 
 
Fig. 2.3. Dissolution mechanism of silicon in hydrofluoridric acid (HF) [17]. 
 
Due to the polarizing influence of the Si–F bond, another F– ion can attack and bond under 
generation of an H2 molecule and injection of one electron into the substrate (steps 2 and 3). 
The polarization induced by the Si–F groups reduces the electron density of the Si–Si 
backbonds; these weakened bonds will now be attacked by HF or H2O (step 4) in a way that 
the silicon surface atoms remain bonded to hydrogen atoms (step 5). The silicon tetrafluoride 
molecule reacts with the HF to form the highly stable H2SiF6. In this work, microcavities 
constituted by a λ/2 layer (optical thickness) sandwiched between two 9.5 period Bragg 
reflectors (BRs), were obtained alternating low (L) and high (H) refractive index layers whose 
thicknesses satisfy the Bragg relationship nHdH + nLdL = mλB/2 where m is an integer and λB is 
Bragg wavelength. The microcavities were prepared by electrochemical etching of highly 
doped p
+ crystalline silicon (0.001 Ω cm resistivity, <100> oriented, 500 μm thick) in HF 
solution (HF:ethanol 1:1) in dark at room temperature (RT) [6–9]. Before the anodization 
process the silicon substrates were immersed in HF solution for 2 min to remove the native 
oxide layer. Since the PSi fabrication process is self-stopping, it is possible to obtain adjacent 
layers with different porosities by changing the current density during the electrochemical 
etching [20]. A current density of 200 mA cm
-2 
for 1.2 s was applied to obtain low refractive 
index layers (nL=1.542; dL =125 nm) while a current density of 100 mA cm
-2
 was applied for 
1.4 s for high refractive index layers (nH=1.784; dH = 108 nm). After electrochemical process, 
CHAPTER 2  OLIGONUCLEOTIDES-MODIFIED POROUS SILICA OPTICAL DEVICES FOR LABEL-FREE BIOSENSING  
 
15 
 
pores dimension was increased to favour the infiltration of biological matter by rinsing the 
fresh-made PSi microcavities in a KOH ethanol solution (1.5 mM) for 15 min [9]. Figure 2.4 
shows scanning electron microscope (SEM) top view images of PSi structure and histogram 
of pores size distribution, which reveals a mesoporous morphology constituted by pores with 
an average value of 30 nm. PSi is a material characterized by a high chemical reactivity; if 
stored in ambient air, the texture becomes partially oxidized and the refractive index changes 
[21]. To stabilize the PSi and eliminate the problem of aging, the thermal oxidation of the 
structure is generally used. The thermal oxidation was performed in pure O2 by a two-step 
process: pre-oxidation at 400 °C for 30 min followed by oxidation at 900 °C for 15 min. The 
oxidation reduces or completely removes the Si–H from the skeleton substituting it by SiO2, 
that isotropically grows also into the pores [22]. 
 
Fig. 2.4. SEM image of mesoporous silicon and corresponding histogram of pores size 
distribution. Scale bar corresponds to 200 nm. 
2.2 Aminosilane-modified porous silica devices  
A key requirement of PSi use in biosensing is the high stability of the material during 
experiments in biological solutions, avoiding the degradation of the biosensor and/or possible 
alteration of measurement results [23]. Moreover, for biosensor development the PSi surface 
should provide coupling points for the immobilization of biomolecules, preserving their 
specific functionalities through a good control of their orientation and organization on the 
surface. There are many strategies for modifying PSi surfaces, among them self-assembled 
monolayers-modified PSi surfaces is the most attractive one [24]. For biosensing applications 
of PSi, self-assembled monolayers generate layers with well-defined packing that improve the 
surface stability and coupling points for the immobilization of bioprobes [25]. The two most 
popular silane coupling agents are 3-amino-propyl-triethoxysilane (APTES) and 3-amino-
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propyl-dimethyl-ethoxysilane (APDMES) able to form an aminosilane layer on PSi surface 
through the formation of Si–O–Si covalent bonds. Both reagents contain a short 3-
aminopropyl group and provide a distal amine group for biomolecule attachment. Before 
functionalizing PSi with aminosilane, the reaction conditions were optimized on crystalline 
silicon to this aim. Eight different silane films, namely S1–S8, were prepared by incubating 
silicon substrates at room temperature (RT) for 30 or 60 min, into 5% silane solutions 
prepared by direct solution of silane compounds in ethanol or anhydrous toluene, (Table 2.1). 
 
 
Fig. 2.5. Scheme of cristalline silicon surface modification by APTES and APDMES. 
 
The scheme of silanization process performed on silicon surface is illustrated in Fig. 2.5. The 
thickness and uniformity of APTES and APDMES layers were investigated by spectroscopic 
ellipsometry (SE). Table 2.1 reports SE values: film thickness of siloxanes increases with time 
deposition; 60 min samples are always thicker than 30 min samples in every combination of 
solute (APTES and APDMES) and solvent (ethanol and toluene). Moreover, APTES thin 
films are thicker than APDMES ones, since APTES is able to reticulate, while APDMES is 
not. Best results in terms of aminosilane films homogeneity, also assessed by atomic force 
microscopy analysis (data non shown), were obtained on samples incubated in solutions 
containing 5% aminosilane in dry toluene for 30 min. These conditions were used to graft the 
silane molecules on the PSi surfaces. The surface of PSi microcavities were hydroxylated by 
Piranha solution (H2O2:H2SO4 1:4 at RT, 30 min) thus increasing their reactivity by 
CHAPTER 2  OLIGONUCLEOTIDES-MODIFIED POROUS SILICA OPTICAL DEVICES FOR LABEL-FREE BIOSENSING  
 
17 
 
introduction of –OH groups. After Piranha treatment, samples were extensively washed in 
milli-Q
®
 water flow and then silanized by immersion in different 5% aminosilane solutions, 
APTES or APDMES, in dry toluene for 30 min at RT. Excess of ungrafted silanes was 
removed by rinsing samples three times in dry toluene for 2 min. Measurement of transducer 
optical spectra by spectroscopic reflectometry is very useful to give quantitative information 
about PSi stability, chemical functionalization and analyte biomolecular recognition. 
 
 
Tab. 2.1. Sample preparation conditions and ellipsometry data. 
 
Optical transducers respond to refractive index change associated with the binding of 
inorganic/organic matter as a result of surface chemical functionalization and/or recognition 
of analyte [26]. The replacement of air in the pores increases the average refractive index of 
PSi layers, resulting in a shift of reflectivity spectra towards greater wavelengths. In Figure 
2.6, reflectivity spectra of PSi microcavities before (i.e., PSi multilayers thermally oxidized) 
and after silanization process by APTES and APDMES are reported; in both cases, red shifts 
of spectra can be observed. The phenomenon is due to formation of a thin silane film on pore 
walls, which increases the average refractive indexes of PSi layers. In particular, a red shift of 
21 nm has been registered for microcavity treated by APTES and of 6 nm in case of APDMES 
silanized structure. These different values are due to diverse thicknesses (t) of silane layers 
coating internal surface of pores, quantified applying the following equation [27]: 
)(4 beforeporelayer
before
pore
after
porepore nn
D
t
nnn         [2.1] 
where npore is the increase of pores refractive index due to presence of silane layer, D is the 
pores diameter, nlayer is the refractive index of silane layer, 
npore
before
silanization process.  
Sample Silane Solvent Incubation time (min) Silane thickness (Å) 
S1 Aptes 5% Ethanol 30 5.5±0.3 
S2 Aptes 5% Ethanol 60 17.3±0.3 
S3 Aptes 5% Toluene 30 26.4±0.3 
S4 Aptes 5% Toluene 60 81.3±0.8 
S5 Apdmes 5% Ethanol 30 0.2±0.2 
S6 Apdmes 5% Ethanol 60 3.0±0.3 
S7 Apdmes 5% Toluene 30 4.2±0.3 
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Fig. 2.6. A) Reflectivity spectra of a PSi microcavity before (solid line) and after (dash line) 
the APTES functionalization. (B) Reflectivity spectra of a PSi microcavity before (solid line) 
and after (dash line) the APDMES functionalization. 
 
In our case, 
npore
before = nair =1 nlayer=nAPTES=nAPDMES=1.46(0.01), measured by spectroscopic 
ellipsometry, and D=15 nm (because oxidized structure) [6–8]. By changing thickness t (from 
0.1 to 1 nm, by 0.1 step) in Eq. 2.1, a set of npore values, which have been used to calculate 
PSi microcavity spectrum red-shifts, were obtained [28]. Red-shift observed in case of 
APTES silanization (21 nm) corresponds to 0.7 nm thick layer computed (npore=0.086); the 
lower shift measured for APDMES treatment (6 nm) corresponds to a layer with a calculated 
thickness of 0.2 nm (npore==0.024). This result depends on the ability of APTES to 
polymerize, because it has three potential points to attach PSi substrate or other silane 
molecules, while APDMES cannot do it, since it has an only one point to attach substrate (see 
binding schemes in Figure 2.4) [29].  
The variation of surface wettability before and after silanization processes was characterized 
by measurements of water contact angle (WCA), as shown in Figure 2.7. The control of 
surface wettability plays a key role in studies of biomolecules immobilization. The oxidized 
PSi is strongly hydrophilic, resulting in a WCA value of (12.6±0.8)°; APTES, with its alkyl 
chain and three ethoxy groups, induces an increase of the WCA to (34±1)° corresponding to a 
reduction in the degree of hydrophilicity; APDMES, characterized by the same alkyl chain but 
two methyl groups, creates a surface with a higher WCA (42±4)°. 
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Fig. 2.7. Water contact angle measurements performed on oxidized porous silicon before and 
after APTES and APDMES modifications . 
 
 
Fig. 2.8. AFM images of bare oxidized PSi and aminosilane modified oxidized PSi surfaces . 
 
Atomic force microscopy (AFM) was used to characterize the samples surface before and 
after aminosilane modification. The AFM images of bare oxidized PSi, APTES- and 
APDMES-modified PSi surfaces are reported in Figure 2.8. AFM image of porous SiO2 
reveals a sponge-like structure characterized by hillocks and voids randomly distributed on 
the whole surface; pores size can be estimated to be on the order of 20 nm. After APTES 
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grafting (porous SiO2+APTES), most voids disappear due to partial pore cloaking by silane 
layer coating the pore walls. Quite same result is obtained in the case of APDMES 
modification (porous SiO2+APDMES): even if APDMES forms a thinner layer, voids in the 
porous matrix are strongly reduced. 
2.3 In situ synthesis of oligonucleotide on porous silica  
Fabrication of biosensors and microarrays, and more generally of each inorganic device 
coupled to a biomolecule, has its main issue in bioconjugation (i.e., the immobilization of a 
working biological probe onto a solid surface). Bioconjugation represents a current challenge 
crossing both material sciences and biomedical applications [30, 31]. In order to develop a 
DNA biosensor, the in situ oligonucleotide synthesis on PSi surfaces can be chosen as an 
alternative method to the traditional ex situ immobilization of DNA fragments. In situ 
technique allows to covalently biofunctionalize amino-modified PSi structure, directly 
growing oligonucleotide sequence on the surface, thus obtaining high ON surface coverage 
and flexibility in the choice of the probe sequence [32]. After a preliminary characterization 
of PSi-APTES (PSi-La) and PSi-APDMES (PSi-Lb) devices, a comparison of their 
effectiveness for in situ ON synthesis was evaluated by exposing the devices to the same 
synthesis. Solid phase ON syntheses were performed by a PerSeptive Biosystem Expedite 
8909 DNA automated synthesizer. The 13-mer polythymine ON strand was assembled on the 
different aminosilane modified microcavities, following phosphoramidite chemistry by 
thirteen growing cycles [33, 34]. PSi structures, PSi-La, b-NH2 (La = APTES, Lb = APDMES), 
were introduced in a suitable column reactor to be used in the automated synthesizer; the 
syntheses were performed according to the scheme reported in Figure 2.9. In all cases, the 
first reaction step involved the attachment of the 3'-ending nucleobase to the amino group of 
PSi-bound APTES or APDMES. This step required the activation of the protected 
phosphoramidite dissolved in dry acetonitrile via protonation by weakly acidic tetrazole (0.45 
M in acetonitrile). Once the first nucleobase was installed on the solid support, the ON growth 
was obtained by repeating the following sequential steps of the automated ON synthesis: 
Coupling: reaction of the protected phosphoramidite dissolved in dry acetonitrile and 
activated via protonation by weakly acidic tetrazole (0.45 M in acetonitrile) with the 5'-OH 
ON terminal group. 
Oxidation: oxidation of the unstable phosphite triester linkage to the more stable 
phosphotriester by standard  oxidizing solution of iodine in pyridine/acetonitrile. 
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Capping: acylation of the unreacted 5′-OH ON terminal groups by acetic anhydride in 
pyridine and tetrahydrofuran to minimize deletion products and simplify the purification 
process.  
Detritylation: removal of the 5′-dimethoxytrityl (DMT) protecting group from the support-
bound 5′-terminal nucleotide with the deblocking solution of trichloroacetic acid in 
dichloromethane (3% w/w). 
The amount of DMT cation released by acid treatment was used as a direct measure of the 
efficiency of the ongoing synthesis. The release of the protecting group generates a bright red-
orange colour solution in which the quantity of the DMT cation can be measured online by 
UV-Vis spectroscopy at 495 nm (ε = 71,700 M–1cm–1). At the end of each growing cycle the 
support was thoroughly washed with acetonitrile before the beginning of the successive cycle. 
The quantification of functionalization yield of each synthesis cycle by ultraviolet (UV) 
spectroscopy after detritylation of 5’-dimethoxytritil (DMT) group released in solution, was 
performed [15]. In the first one, yield is quite constant and high (approximately 100%  
experimental errors), while in the second one there is a dramatic decrease: each solid phase 
synthesis step involves an increasing inefficiency as oligonucleotide length is increased. 
Efficiency of coupling to PSi-APTES (Figure 2.10 (A)) falls just after the forth-base growth; 
this threshold is pushed after the seventh thymine in case of PSi-APDMES (Figure 2.10 (B)). 
 
Fig. 2.9. Synthetic procedure for solid phase synthesis of aminosilane PSi-T13 (PSi-La,b-T13), 
i) standard automatic synthetic cycle; ii) phosphates-deprotection, K2CO3 (0.05 M)/MeOH 
dry. 
 
 
Aminosilane IT13 F (mol/g) SSA (m
2
/g) F (nmol/cm
2
) 
APTES 0.12±0.01 (2.6±0.2)x10-5 39 0.067±0.005 
APDMES 0.17±0.01 (3.7±0.2)x10-5 43 0.086±0.005 
 
Tab. 2.2. Functionalization values calculated for the PSi structures modified with the two 
aminosilanes.  
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Fig. 2.10. Coupling yield calculated by means of DMT measurements performed on the PSi 
samples silanized with APTES (A) and with APDMES (B). 
 
In general, coupling yield to PSi-APDMES is greater than that of PSi-APTES for all the 
synthesis cycles, up to the 13
th
 thymine (T13). This experimental result can be reasonably 
ascribed to higher steric hindrance of pores caused by thicker APTES film with respect to 
APDMES one. UV intensity measurements at T13 (IT13, first column of Table 2.2) also enable 
the quantification of functionalization F in terms of mol/g for both samples (PSi-La,b weight 
about 0.3 mg) by using Lambert-Beer formula (molar absorptivity =71700 M-1cm-1). Data 
obtained are reported in Table 2.2 together with the specific surface area (SSA) of PSi-La,b. PSi 
samples “as etched” are characterized by SSA values of about 100 m2/g measured by 
Brunauer-Emmett-Teller (BET) method [15]; the KOH process induces an increase of 
porosity of about 6% corresponding to an increase of SSA equal to 106 m
2
/g, quantified by 
spectroscopic reflectivity (50 nm blue shift of the microcavities spectra, data not shown here). 
On the contrary, thermal oxidation decreases SSA to 60% (from 106 m
2
/g to 43 m
2
/g), due the 
isotropic silica growth also into the pores [35]. PSi-La, b SSA values, shown in Tab. 2.2, have 
been calculated by applying a simplified model based on the cylindrical shape of the pores 
taking into account the thickness of silane layer on the pore walls (0.7 nm for APTES and 0.2 
nm for APDMES). Samples functionalization in terms of nmol/cm
2
, last column in Table 2.2, 
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is the ratio F/SSA. The better coupling yield obtained for APDMES-modified PSi results in 
higher number of moles per square centimetre with respect to the APTES one (about 0.09 vs 
0.07). The results demonstrated the possibility of synthetizing oligonucleotide sequence on a 
silanized porous matrix without harming its structure, and monitoring ON synthesis by optical 
spectroscopy. Furthermore, chemical stability of the support material turns to be key issue for 
hybridization experiment. Since, APDMES-PSi sample shown an higher functionalization due 
to less steric hindrance of pores than APTES one, it was used for hybridization studies with 
complementary and not complementary sequence.  
 
 
Fig. 2.11. Reflectivity spectra of the PSi microcavity after the APDMES functionalization 
(solid line), after the T13 synthesis (dash line), after the C20 incubation (short dash line), and 
after the A20 incubation (dot line) 
2.4 Label-free optical detection of DNA-DNA hybridization 
In molecular biology, hybridization (or hybridisation) is a phenomenon in which single-
stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) molecules anneal to 
complementary DNA or RNA [36]. Hybridization is a basic property of nucleotide sequences 
and is the underlying mechanism of molecular recognition of DNA-biosensors. The 
hybridization of DNA-PSi (PSi-Lb-T13) biosensor to complementary (Fluo-dA20) and non-
complementary (Fluo-dC20) oligonucleotide sequences has been monitored by spectroscopic 
reflectometry and, for comparison, also by fluorescence microscopy. Figure 2.11 shows 
reflectivity spectra of device before synthesis process, after T13 synthesis, and after 
complementary DNA interaction: a red shift of 22 nm has been detected after T13 synthesis, 
which is a value higher than 11 nm obtained in case of oxidized multilayer [15]. This red shift 
increase is due to a higher chemical stability of the PSi platform during the synthesis process. 
The spectrum shifts further of 7 nm after the complementary DNA exposure, thus 
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demonstrating the detection of DNA-DNA interaction. In Figure 2.11 it is also possible to 
observe how exposure to non-complementary sequence does not induce any shift, confirming 
specificity of biosensor. Optical monitoring of T13-A20 hybridization has also been proved 
by fluorescence analysis. In Figure 2.12, bright field (A) and fluorescence (B) images of PSi-
Lb-T13 surface after incubation with labelled complementary (Fluo-dA20; left image) and 
non-complementary (Fluo-dC20; right image) sequences, are reported. While in bright field 
imaging surface samples appeared indistinguishable, switching from bright-light source to 
fluorescence-light source, a fluorescence (maximum peak value = 73 counts; average intensity 
=34 counts) on exposure to complementary ON sequence was observed. On the contrary, chip 
incubated with non-complementary sequence appeared completely dark (maximum peak 
value= 7 counts; average intensity = 5 counts), further confirming the specificity of the DNA-
biosensor. 
 
 
Fig. 2.12. Bright field (A) and fluorescence (B) images of the PSi surface functionalized with 
T13 after the incubation with the solutions containing Fluo-dA20 (left) and Fluo-dC20 (right). 
Scale bar= 1 mm. 
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3 LABEL-FREE PSI APTASENSOR FOR HUMAN THROMBIN 
DETECTION 
 
(Papers J3, J4, P2, P4) 
Aptamers are an emerged class of single-stranded oligonucleotides generated from SELEX 
techniques [1, 2]. Aptamers by folding into well-defined secondary or tertiary structures are 
able to specifically bind their target molecules with high affinity, and so are classified as 
powerful ligands for diagnostic and therapeutic applications [3]. Aptamers as bioprobes 
opened new generation of DNA biosensors called aptasensors [4]. Due to their unique 
properties, aptamers provide more advantages than conventional bioprobes (e.g., antibody) [3, 
5]. One of the most studied G-quadruplex-based aptamer is thrombin-binding aptamer (TBA). 
It demonstrated able to bind α-thrombin, a key protein involved in the clotting process, 
preventing the pathological process of thrombosis [6, 7]. In this chapter, the realization of 
high sensitive and reversible PSi-based TBA biosensor by in situ synthesis for the detection of 
human α-thrombin molecule is described. Human thrombin is a serin protease, also known as 
coagulation factor II, that converts soluble fibrinogen (factor I) into insoluble strand of fibrin 
(factor Ia) with crucial role in coagulation and hemostatsis [6]. The equilibrium between 
production and inhibition of this enzyme prevents hemorrhagic or thrombotic phenomena. 
The concentration of thrombin in healthy subject can be almost absent until getting up from 
nM to µM level in the coagulation process [7]. High level of thrombin in the blood (beyond 
the normal coagulation phenomenon) could determine pathological coagulation giving 
thrombotic disorder such as thromboembolism, ischemic stroke etc., fatal for human health 
[8]. Moreover, some disorders on central nervous system (SNC), such as Alzheimer, could be 
potentially related to high levels of thrombin, which involves degeneration of neurons and cell 
death; as well as an involvement of this serin-protease in cancer disease [9, 10]. In this chapter, 
preliminary studies on mixed-ON in situ synthesis and PSi stability to new deprotection ON 
condition are reported. Then, the fabrication and characterization of a selective, sensitive and 
reversible PSi-aptasensor through in situ synthesis for thrombin molecule detection is 
described.  
3.1 Mixed oligonucleotide-modified porous silica 
The high selectivity of oligonucleotides and derivatives is a crucial aspect for DNA-
biosensors development [11]. The use of mixed-sequence of oligonucleotides and an 
increasing of probe length have been shown to enhance the selectivity of DNA-biosensor, 
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particularly for the detection of non-nucleic acid targets [12]. The 19-mer mixed sequence 
oligonucleotide 5'-GATTGATGTGGTTGATTTT-3' was assembled on two different 
aminosilane modified microcavities, following phosphoramidite chemistry by nineteen 
growing cycles. The fabrication and aminosilane-modification of PSi microcavities by APTES 
or APDMES were performed following the procedures described in Chapter 2. Before the 
synthesis of mixed ON sequence the stability of amino-modified-structures to standard 
deprotection condition of nucleobases, was evaluated. Alkaline solutions are commonly used 
for the standard deprotection of nucleobases with drawback to easily corrode the silicon 
skeleton; so a trade-off between PSi surface passivation and PSi-friendly ON deprotection 
conditions of mixed ON on PSi supports is required. The reflectivity spectra and graphs of 
peak-shift vs incubation time for APTES- and APDMES- modified PSi before and after 
treatment with 33% aqueous ammonia (17 h, 55 °C) used in the standard deprotection 
condition are reported in Figure 3.1. The stability of the surfaces were tested by a full dip in 
ammonia solution for different times (30, 60, 90, 120 min). The results showed that the 
destructive effect of ammonia solution was about the same for both samples: a blue shift of 25 
or 50 nm was detected after 30 min or 1 h, respectively, and the complete dissolution of the 
silicon matrices occurred after 2 h. Because aqueous ammonia could not be used in 
deprotection steps, the saturated methanolic ammonia dry solution as an alternative strategy 
was tested [13]. Both the two aminosilane-modified PSi structures were highly stable at this 
condition. In both devices a perfect overlap of spectra before and after the treatment was 
observed, thus confirming the feasibility of this deprotection strategy (data not shown). Once 
deprotection conditions were checked and set up for PSi samples, amino-modified PSi 
structures, were used as supports for automated in situ solid phase mixed-ON synthesis using 
the standard phosphoramidite chemistry. The amount of 5'-dimethoxytrityl released after the 
detritylation step was used to quantify the functionalization yield of each synthesis cycle by 
UV/Vis spectroscopy (Figure 3.2). Up to the fourth coupling cycle almost the same coupling 
yield for both aminosilane-functionalized PSi supports was observed. From the fifth cycle on, 
the coupling yields dropped for both supports, even if higher functionalization yields were 
generally observed for PSi supports functionalized with APTES. Both PSi microcavities gave 
a medium yield process, mainly due to average pore size (about 20 nm). PSi photonic devices 
with pore dimensions greater than that value, but always compatible with high optical quality 
response in the visible-near infrared, could be suitable to maximize yield of mixed-ON 
synthesis. Figure 3.2 also shows the reflectivity spectra of devices before and after the in situ 
synthesis process: red shifts of 60 nm and 70 nm were detected respectively for APTES- and  
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Fig. 3.1. A) Reflectivity spectra of APTES modified PSi microcavity before (solid line) and 
after 30 (dashed line) and 60 min (dotted line) of incubation in 33% NH3 at 55°C. 
Corresponding peak shift vs incubation time. B) Reflectivity spectra of APDMES modified PSi 
microcavity before (solid line) and after 30 (dashed line) and 60 min (dotted line) of 
incubation in 33% NH3 at 55°C. Corresponding peak shift vs incubation time. 
 
APDMES-modified devices, thus indicating that more ON had grown on the latter device 
with respect to the first one. This experimental result is ascribed to the less steric hindrance of 
pores due to thinner APDMES film, as previously described in Chapter 2. After to in situ 
synthesis, the samples were exposed to dry NH3/MeOH solution in order to deprotect the 
mixed-ON sequence. A blue shift of only 2 and 4 nm, attributed to the removing of bound N-2 
isobutyryl (on G), N-6 benzoyl (on A) and N-4 benzoyl (on C) from PSi-APTES and PSi-
APMES was observed, respectively (data not shown). The ability of dry NH3/MeOH solution 
to completely deprotect the PSi-aminosilane-bound ON, was also confirmed by 
chromatographic analysis, proving complete cleaving of the amide bound N-2, N-4 and N-6 
groups after 3 hours at RT. Furthermore, the ammonia in dry MeOH is able to quickly remove 
the 2-cyanoethyl phosphate protecting group [13]. This data, together with findings on the 
compatibility with the silicon structure, indicate the dry NH3/MeOH solution as the best 
choice to deprotect mixed-ON sequence, giving the possibility of realizing more specific 
DNA-PSi biosensor without promoting the basic hydrolysis on the support, which instead 
occurs in aqueous conditions. 
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Fig. 3.2. A) Reflectivity spectra of APTES modified PSi microcavity before (solid line) and 
after ON synthesis (dashed line). Corresponding UV intensity vs ON synthesis. B) Reflectivity 
spectra of APDMES modified PSi microcavity before (solid line) and after ON synthesis 
(dashed line). Corresponding UV intensity vs ON synthesis. 
 
The mixed-ON sequences were detached form PSi solid supports, purified by High 
Performance Liquid Chromatography (HPLC) and compered to control ON mixed sequence, 
respectively (data not shown). The results showed an incomplete synthesis of both ON 
sequences, confirming the need of a macroporous structure as solid support, in order to 
optimize the mixed-ON synthesis.  
3.2 Anti-thrombin aptamer -modified porous silica biosensor 
TBA PSi aptasensor for label-free thrombin detection was developed via solid phase synthesis 
on macroporous silicon device. Macroporous silicon structure with pore size included 
between 100 and 200 nm (Figure 3.3) was fabricated by electrochemical etching of n-
crystalline silicon (0.01-0.02 Ω cm resistivity, ⟨100⟩ oriented and 500 μm thick) in 
hydrofluoric acid (HF 5% in weight)/ethanol solution at room temperature (RT). A current 
density of 20 mA/cm
2
 was applied for 90 s to produce a single layer of PSi with a porosity of 
52% (n = 1.54) and a thickness of 2 μm. 
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Fig. 3.3. SEM image of macroporous silicon and corresponding histogram of pores size 
distribution. Scale bar corresponds to 200 nm. 
 
Before the etching procedure, the silicon substrate was immersed in HF solution for 2 min to 
remove the native oxide layer. Subsequently the thermal oxidation was performed to passivate 
the PSi surface. The PSi structure used acts as a Fabry−Perot interferometer [14]. The optical 
path (nPSiL) of the PSi layer was calculated from the reflectivity spectrum by fast Fourier 
transform (FFT) which displays a peak whose position along the x-axis corresponds to two 
times the optical path (2nPSiL) of the layer [15]. As previously demonstrated, both 
aminosilane compounds (i.e., APTES and APDMES) shown a good protection of PSi 
structures against reagents used for in situ synthesis. In this case, the silanization procedure 
was developed by using APTES thus obtaining a better coating of PSi pores, due to the 
property of the aminosilane to polymerize. Moreover, macroporous silicon structure used for 
the realization of TBA-aptasensor, has a less steric hindrance of pores than mesoporous one 
which requires, on the contrary, aminosilane thin film. 
In Figure 3.4 (A), normal incidence reflectivity spectra are shown for oxidized-PSi layer 
before and after aminosilane-modification and corresponding Fourier transforms (FFT) are 
reported, in Figure 3.4 (B). The FFT peak shift of about 30 nm is due to an increase of the PSi 
layer average refractive index as result of APTES coating of pore walls. PSi-APTES device 
has been exposed to synthesis of TBA based on phosporamidite chemistry, quantifying the 
functionalization yield of each synthesis cycle by UV spectroscopy after detritylation of 5’-
dimethoxytritil (DMT) group released in solution. In Figure 3.5 the synthesis yield for 
PSiAPTES kept fairly constant throughout all TBA synthesis contrary to what was 
previously observed for 19-mer mixed ON synthesis. 
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Fig. 3.4. Reflectivity spectra (A) and correspondent FFT (B) of a PSi oxidized structure before 
(black line) and after (red line) the APTES functionalization. 
 
 
Fig. 3.5. Coupling yield calculated by means of DMT measurements performed on the 
silanized PSi sample with APTES. 
 
The maximized yield synthesis of TBA macromolecule was ascribed to less steric hindrance 
of macroporous structure than mesoporous one allowing the correct and complete bioprobe 
growth [16]. Figure 3.6. shows reflectivity spectra (A) with corresponding FFTs (B) of 
PSiAPTES before and after the in situ synthesis process: a calculated FFT peak shift of 36 
nm confirmed the successful of TBA growth on device making the PSi structure sensitive to 
thrombin detection. The target molecular recognition of DNA-biosensor requires the 
deprotection of each base constituting the ON grown on the PSi. The PSi-aptasensor (PSi-
TBA) was deprotected by ammonia solution under anhydrous conditions (NH3/dry methanol) 
which promotes the effective deprotection of the phosphate and exocyclic amino groups of 
nucleobases without the basic hydrolysis of the PSi . 
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Fig. 3.6. Reflectivity spectra (A) and corresponding Fourier transforms (B) of aminosilane 
modified PSi before (black line) and after the TBA synthesis (red line). 
 
 
 
 
Fig. 3.8. Scheme of TBA structure (A) and TBA-PSi biosensor (B). In presence of thrombin, 
TBA folds into an antiparallel unimolecular G-quadruplex dictating its thrombin-binding 
affinity. 
3.2.1 Human thrombin detection 
Because of TBA capability of inhibiting the activity of thrombin, extensive studies on the 
structure of TBA were carried out to know and demonstrate the binding mode between TBA 
and thrombin [6]. In presence of thrombin and/or monovalent cations, TBA folds into an 
antiparallel unimolecular G-quadruplex dictating its thrombin-binding affinity [7] (Fig. 3.8). 
After the deprotection process, the PSi-aptasensor was exposed to different molar 
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concentration of thrombin solutions (13, 27, 54 and 109 nM). Figure 3.9 shows the optical 
spectra of label-free PSi-aptasensor (A) after interaction with different thrombin concentration 
and corresponding FFTs (B). FFT peak shift is proportional to the amount of analyte (i.e. 
human thrombin). When the control solution of albumin (HSA) at different molar 
concentrations was incubated with PSi-aptasensor surface no obvious peak shift was observed, 
confirming specificity of the aptasensor (Fig 3.10). 
 
 
Fig. 3.9. Reflectivity spectra (A) and corresponding Fourier transforms (B) of TBA-biosensor 
after exposure to thrombin solutions (13, 27, 54 and 109 nM).  
 
 
 
Fig. 3.10. Reflectivity spectra (A) and corresponding Fourier transforms (B) of TBA-
biosensor after exposure to the control HSA solutions (13, 27, 54 and 109 nM). 
 
3.2.2 Reversibility, sensitivity, and limit of detection of PSi aptasensor 
The reversibility of biosensor is an advantageous requirement due to the continuous sensing 
measurement by the same device, resulting beneficial in terms of money and time consuming 
[17]. The reversibility of TBA-biosensor was proved by exposing the device to melting 
temperature of TBA. DNA melting, also called DNA denaturation, is the process by which 
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double-stranded deoxyribonucleic acid unwinds and separates into single-strand through the 
breaking of hydrogen bonds between the bases [18]. At melting temperature of 53 °C, TBA 
straightening loses the typical G-quadruplex structure and then thrombin binding affinity. 
However, the process is reversible thus cooling the temperature the aptamer comes back in the 
form it was originally [19]. The Figure 3.11 reports reflectivity spectra (A) with 
corresponding FFTs (B) of TBA-biosensor before (i.e. analyte saturated) and after restore, and 
after exposure to thrombin. The results showed that spectrum of restored-aptasensor (R-TBA-
biosensor) coincides to that of TBA-biosensor before thrombin detection, confirming the 
reversibility of the aptasensor. A FFT peak shift of 68 nm was measured after exposure of R-
TBA-biosensor to thrombin solution (109 nM) demonstrating a preserved functionality of the 
biosensor to recognize thrombin. 
 
 
Fig. 3.11. Reflectivity spectra (A) and corresponding Fourier transforms (B) of TBA-
biosensor after TBA synthesis (black line), after recondition (red line), and after exposure to 
solution of thrombin (blu line).  
 
Since TBA acts as inhibitor of enzymatic activity of the thrombin, Michaelis–Mentens-like 
equation was used as model of enzyme kinetic to describe TBA–thrombin interaction [20]. 
The optical thickness of TBA-biosensor as function of thrombin concentration is reported in 
Figure 3.12; data were fitted by OriginLab Software™ by using Michaelis and Mentens-like 
equation:  
𝑦 = 𝛥𝜆𝑚𝑎𝑥 
[𝑇𝐵]
𝐾𝑚 + [𝑇𝐵]
 
where Δλmax represents the maximum rate achieved by the system at maximum (saturating) 
substrate concentrations; the affinity constant Km is the substrate concentration at which the 
reaction rate is half of Δλmax [20]. Km constant gives information about the affinity of the 
enzyme toward the substrate: a low value of Km indicates a high affinity for the substrate. The 
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calculated Km value for PSi-aptasensor is 18.6 ± 9.2 nM, sensitivity of 1.3 ± 0.3nm nM
-1
 
(calculated in the range of linearity of system response) and limit of detection (LOD) of 4.0 ± 
0.9 nM are comparable to accurate methods for thrombin detection [20–22]. 
 
Fig. 3.12. Optical thickness of TBA-biosensor vs thrombin concentration. Experimental data 
(black symbols) were fitted using Michaelis-Menten-like kinetic model. 
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4 DIATOMITE: A NATURAL NANOSTRUCTURED MATERIAL FOR BIOMEDICAL 
APPLICATIONS  
 
(Papers J5, P3) 
In recent years, emerging natural porous materials for biomedical applications have been 
suggested to overcome the shortcomings of the synthetic porous materials, finding in 
diatomite a viable surrogate [1−3]. Diatomite is a cheap fossil compound formed by 
fragments of diatom siliceous skeletons, with similar physicochemical properties of man-
made fabricated PSi [4, 5]. Due to its peculiar properties such as ordered pore structures, 
amorphous silica, high surface area, tailorable surface chemistry, high permeability, 
biocompatibility, non-toxicity, low cost, optical and photonic properties, diatomite has been 
used in different applications, including optics, photonics, filtration, sensing, biosensing, and 
protein separation [6−12]. The main constituent of diatomite is amorphous silica, approved by 
Food and Drug Administration (FDA) as Generally Recognized as Safe (GRAS, 21 CFR 
Section 573.340) for foods and pharmaceuticals production, and classified in the 3
th
 group of 
“Not classifiable as to its carcinogenicity to humans” by the International Agency for 
Research on Cancer (IARC) [13]. Surprisingly, its use in nanomedicine is still undervalued, 
and only recently diatom frustules have been explored as microcapsules for oral drug 
delivery, resulting in a non-cytotoxic biomaterial with high potential to improve the 
bioavailability of loaded oral drugs by sustaining the drug release and enhancing the drug 
permeability [11]. In this Chapter, the fabrication of diatomite nanoparticles (DNPs) is 
described. A multistep chemical procedure to purify the NPs from organic and inorganic 
impurities, is also reported. The potentialities of DNPs as nanocarrier for drug delivery 
applications through in vitro cytotoxicity and cellular internalization studies, are investigated. 
4.1 Diatomite powder from mining industries to nanovectoring: morphological and 
composition analysis 
Diatomite is a fossil material of sedimentary origin formed by fragments of diatom skeletons, 
called frustules. Frustules of diatoms, single-cell photosynthetic algae largely diffused in 
aquatic environments, are mainly constituted by amorphous silica and are characterized by a 
specific surface area up to 200 m
2
/g [14]. In nature, there are different kinds of diatoms (about 
110,000 species) varying in size (from 2 μm to 2 mm) and morphology [15]. The low cost, 
abundance, easy availability, excellent biocompatibility, non-toxicity, thermal stability, and 
chemical inertness make diatomite an intriguing material for several applications ranging 
from filtration to pharmaceutics [16−19]. Diatomite powder, due to its sedimentary origin, can 
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Fig. 4.1. SEM images of purified diatomite structures (A–E) and particles size histogram (F) 
calculated from (A). 
 
contain some traces of impurities such as organic components and metallic oxides (MgO, 
Al2O3, Fe2O3) coming from the environment. A multistep procedure based on mechanical 
reduction of frustules to NPs and chemical purification treatments, were developed in order to 
make DNPs safer and more biocompatible vehicles for medical applications. About 5g of 
crashed diatomite powered (DEREF Spa, Italy) was resuspended into 250 mL of absolute 
ethanol and sonicated for 18 h to break large aggregates. The dispersion was sieved through a 
nylon net filter with pore size of 41 μm, and then filtered with pore size of 0.45 μm. The 
diatomite nanopowder was purified to remove the organic and inorganic impurities. First, the 
sample was centrifuged and the pellet treated with Piranha solution (2 M H2SO4, 10% H2O2) 
for 30 min at 80°C. Then, the NPs dispersion was centrifuged for 30 min at 13.500 rpm, 
washed twice with distilled water, resuspended in 5 M HCl, and incubated overnight at 80°C. 
DNPs were then centrifuged for 30 min at 13.500 rpm and washed twice with distilled water 
to eliminate HCl residues. The diatomite powder was morphologically characterized before 
and after the processing by scanning electron microscopy (SEM), transmission electron 
microscopy (TEM), and dynamic light scattering (DLS) analysis. Before the processing, 
diatomite resulted as a mixture of fragments with circular, elliptical, elongated, and squared 
shape, with dimension distribution ranging from few microns up to ~40 μm, as shown in 
Figure 4.1. After the mechanical and chemical treatments, diatomite powder appeared as an 
heterogeneous population constituted by nanostructures morphologically different in shape 
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Fig. 4.2. TEM images of bare (a-c) and increasing zoom of the pores of the NPs (d). 
 
and size. As shown in Figure 4.2 (C, D) the porous structure of the NPs is preserved even 
after the breaking of the diatomite powder in nanoparticles, where it is clearly visible the 
hierarchical pore organization on the surface of the diatomite NPs and the mesopores (10 nm 
< pores diameter < 50 nm) inside macropores (pores diameter > 50 nm). Due to their peculiar 
porous nature, diatomite NPs can be very promising for the loading of a wide size range of 
molecules from small molecules to peptides, oligonucleotides, proteins, and antibodies for the 
preparation of targeted NPs for drug delivery applications [20, 21]. Size and surface charge of 
purified DNPs dispersed in water (pH = 7) were determined by DLS. The average size and 
zeta-potential of NPs were 220 ± 90 nm and −19 ± 5 mV, respectively. The negative value of 
zeta-potential is due to the presence of silanol groups on NPs’ surface due to treatment in 
Piranha solution. Compared to other nanocarriers, the nanometric size and morphology of 
these particles make them suitable in drug delivery applications [22].  
The variation in the chemical composition of diatomite powder before and after purification 
treatments was evaluated by energy dispersive X-ray spectroscopy (EDS), photoluminescence 
(PL) and Fourier transform infrared spectroscopy (FTIR) analyses, confirming the 
improvement of the silica nanopowder quality due the removal of impurities. In Figure 4.3, 
EDS spectra show changes in chemical composition of the samples: after cleaning treatments, 
the intensities of peaks corresponding to calcium, iron and aluminum decreased, whereas the 
silica peak increased (Figure 4.3 C, D). Detailed chemical composition of diatomite before 
and after purification treatments is summarized in Table 4.1. In Figure 4.4, the FTIR spectra 
of untreated (A) and purified (B) diatomite, are reported.  
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Fig. 4.3. SEM images of diatomite deposited on silicon before (A) and after (B) purification 
treatments; corresponding EDS graphs (C–D). 
 
Compounds Before Purification (%) After Purification (%) 
SiO2 92.1 94.6 
Al2O3 3.3 2.7 
K2O 1.0 0.8 
CaO 1.8 0.9 
Fe2O3 1.8 1.0 
 
Tab. 4.1. Chemical composition of frustules before and after purification treatments. 
 
After the chemical treatment in acid solutions, the peak at 680 cm
−1
 and the band at 620–580 
cm
−1
 related to Si−O−Fe and Fe−O−Fe bonds, respectively, disappeared due to the removal of 
metallic impurities from the diatomite amorphous silica matrix. Under UV excitation (325 
nm), diatomite samples showed a blue photoluminescence, clearly visible by naked eye. Even 
if the origin of this emission is not completely clear, it is commonly believed that it is mainly 
originated from surface defects including −OH groups and oxygen vacancies [23]. Laser 
pumping generates excited electrons whose radiative decay produces photoluminescence 
emission. Figure 4.4 A shows the comparison between photoluminescence spectra of 
diatomite before and after treatments. The untreated sample was characterized by a weak 
signal with three main features peaked at 390 nm (3.18 eV), 460 nm (2.7 eV), and 500 nm 
(2.48 eV). After treatment, the peak at 390 nm became weaker, another peak at 423 nm (2.93 
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eV) appeared, while the feature at 500 nm shifted to 490 nm (2.53 eV). These modifications 
were due to the removal of metallic impurities from the frustule surface, accordingly to FTIR 
characterization (Figure 4.4 B). The absence of impurities significantly modified the PL 
signal changing reactions of energy transfer by surface radiative recombination. 
 
 
Fig. 4.4. PL (A) and FTIR (B) spectra a of diatomite before (untreated) and after (treated) 
purification treatments. 
 
4.2 Diatomite nanoparticles: toxicity and cell internalization studies 
A critical issue for biomedical applications of new nanocarriers for drug delivery is the 
evaluation of their potential toxicity and biocompatibility [24]. In vitro cytotoxicity of DNPs 
was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, 
a method based on the reduction of MTT by cellular oxidoreductases of viable cells, that yield 
a crystalline blue formazan product. Human lung epidermoid carcinoma cells (H1355) were 
incubated with different concentrations of DNPs for 24, 48 and 72 h. The results obtained are 
reported in Figure 4.5. The exposure of H1355 cells to increasing nanoparticle concentrations 
(20 μg/mL, 100 μg/mL, 200 μg/mL and 300 μg/mL) induced very low toxicity being the 
average viability of the cells slightly lower than 100%. This result also demonstrated that the 
irregular shape of DNPs did not influence cell growth and morphology. In conclusion, the 
MTT assay showed that H1355 cell viability was not affected even after 72 h of exposure to 
DNPs concentration up to 300 μg/mL, thus confirming their usability as nanovectors in 
nanomedicine [25, 26]. NPs cell uptake was studied by using labelled-DNPs and confocal 
microscopy analysis. Purified NPs were amino modified with a 5% (v/v) APTES solution in 
absolute ethanol, stirring 1 h at room temperature. After this step, the sample was centrifuged 
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for 30 min at 13.500 rpm and supernatant discarded. The functionalized DNPs were washed 
twice with absolute ethanol and the collected pellet was incubated for 10 min at 100°C 
(curing process). The silanization of DNPs was evaluated by FTIR spectroscopy. The 
comparison between FTIR spectra of bare NPs (A) and APTES-functionalized powders (B) is 
reported in Figure 4.6. The peak of Si–O–Si bond at 1100 cm-1, characteristic of diatomite 
frustules, is well evident in both spectra. Before APTES functionalization, it is also detected 
the peak at 3700 to 3200 cm
-1
 corresponding to Si–OH group. The spectrum of functionalized 
sample showed the silane characteristic peaks in the range between 1800 and 1300 cm
-1
 (see 
the inset of Figure 4.6); in particular, the peak at 1655 cm
-1
, corresponding to imine group and 
the peak at 1440 cm
-1
, corresponding to asymmetric deformation mode of the CH3 group, 
were observed [27]. FTIR characterization clearly demonstrated the silanization of silica 
nanoparticles. Diatomite NPs were labelled by tetramethylrhodamine isothiocyanate (TRITC).  
 
 
Fig. 4.5. Cytotoxicity assessment of DNPs using MTT assay. Cell viability of H1355 cells 
treated with 20, 100, 200 and 300 μg/ml of NPs for 24, 48 and 72 h at 37 °C. Data represent 
the mean ± s.d. (n=3). Cell viability was expressed as the percentage of viable cells compared 
with cells cultured without nanoparticles as control (100%). 
 
H1355 cells have been incubated with the labelled NPs (DNPs*) at increasing concentrations 
(5, 10, 15, µg/mL) for 24 h. Figure 4.7 shows representative confocal microscopy images of 
cells treated with DNPs* compared to untreated cells as control. Cell nuclei were stained with 
Hoechst 33342 (blue), cell membranes were stained with WGA-Alexa Fluor 488 (green), and 
DNPs were labelled with TRITC (red). Images show an increase of fluorescence intensity at 
increasing labelled-DNPs concentration and a homogeneous particles distribution in the 
cytoplasm.  
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Fig. 4.6. FTIR spectra of DNPs before (A) and after (B) APTES functionalization. 
 
 
Fig. 4.7. Confocal microscopy images of H1355 cells incubated with different concentrations 
of DNPs* (A), and cell fluorescence intensity analysis (B). Scale bar corresponds to 20 μm.  
 
The cell fluorescence intensity vs labelled NPs concentration is reported in Figure 4.7 B; 
fluorescence values were calculated for each cell from the TRITC images of Figure 4.7A. 
Data showed an increase of the fluorescence intensity up to about 10 μg/mL. A saturation of 
the signal can be observed for NP concentrations higher than 10 μg/mL. To prove the 
internalization of the carriers in the cells, images at different focal depth were recorded. 
Figure 4.8 shows that going from upper cell surface to the focus inside the cells, an increase 
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of red diatomite fluorescence can be observed thus indicating the uptake of labelled-DNPs by 
H1355 cells. These results showed that an efficient NPs uptake into the cytoplasm of cancer 
cells, demonstrating that DNPs could represent a promising tool for the delivery of anticancer 
molecules. 
 
 
Fig. 4.8. Confocal microscopy image with different focal depth of H1355 cells incubated with 
10 μg/mL of DNPs*. 
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5 BIONGINEERED DIATOMITE NANOVECTORS FOR DRUG 
DELIVERY IN CANCER THERAPY  
 
(Papers J6, J7, P5) 
The application of nanotechnology in the cancer therapy is expected to solve a number of 
issues associated with conventional therapeutic agents, including lack of targeting capability, 
nonspecific distribution, systemic toxicity, and low therapeutic index [1, 2]. Nanotechnology 
has provided the opportunity to get direct access of the cancerous cells selectively with 
increased drug localization and cellular uptake, making the therapy more patient compliance 
and efficient. Moreover, nano-based systems allow delivery of poor water solubile molecules 
(at least, most the anticancer drugs) difficult to administer and can also protect the new 
therapeutic molecules such oligonucleotide analogs (e.g., siRNA) from degradation, 
preserving their therapeutic efficacy while in blood circulation [3, 4]. Thus, the aim of 
nanomedicine in cancer therapy is the production of nanoscale devices to enhance the 
bioavailability of drug molecules, improving the tumor-targeting and reducing the systemic 
drug toxicity. In this Chapter the realization of biofunctionalized DNPs for drug delivery in 
cancer cells is described. Since the silica surface of diatomite is covered by silanol (SiOH) 
groups, it can be easily modified with functional reactive groups (−NH2, −COOH, −SH, and 
−CHO) for the conjugation of biomolecules (e.g., DNA, antibodies, and enzymes) in order to 
prepare bioengineered devices. Different functionalization procedures for the preparation of 
bioengeneered DNPs are described, and the results on the effective enhancement of the 
DNPs’physicochemical properties, biocompatibility, cellular uptake and drug delivery, are 
presented. 
5.1 Diatomite biosilica nanocarriers for siRNA transport inside cancer cells  
The availability of the human genome sequence has revolutionized the strategy of employing 
nucleic acids with sequences complementary to specific target genes as new promising tools 
for therapeutic targets [5]. Development of sequence-specific DNA or RNA analogs that can 
block the activity of selected genetic sequences offers the possibility of rational design with 
high specificity, lacking in many current drug treatments for various diseases, at relatively 
inexpensive costs. Molecular therapy using small interfering ribonucleic acid (siRNA) has 
shown to be a powerful approach for silencing gene associated with a variety of pathologic 
conditions caused by abnormal gene overexpression or mutation, such as various cancers, 
viral infections, and genetic disorders [6]. However, siRNA require delivery carriers for 
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protection from nucleases and other environmental agents and to facilitate entry into the cell, 
thus improve its systemic delivery. Its conjugation to nanovectors (including liposomes, gold, 
magnetic and porous silicon nanoparticles, quantum dots) results to be possible strategies to 
overcome these challenging problems [7, 8].  
5.1.1 Study of siRNA loading into diatomite nanoparticles (DNPs) and in vitro release 
Porous diatomite nanocarriers were bioconjugated with siRNA in order to test their drug 
delivery capability. Labelled-siRNA (siRNA*) complexed with a poly D-Arg peptide, was 
loaded onto APTES-modified DNPs, following the functionalization procedure sketched in 
Figure 5.1. 
 
 
Fig. 5.1. Functionalization scheme of diatomite NPs with labelled siRNA (siRNA*). 
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Briefly, APTES-modified functionalized DNPs react with N-(γ-maleimidobutyryloxy) 
sulfosuccinimide ester (sulfo-GMBS), a heterobifunctional cross linker reactive to amino 
groups at one end and to sulfhydryl groups at the other. The N-hydroxysuccinimide (NHS) 
ester reacts with the amino-modified DNPs’ surface as a nucleophile with release of the sulfo-
NHS leaving the group forming an amide bond. Peptide/siRNA* complex (molar ratio 20:1) 
was immobilized on the DNPs’ surface through the thioether bond between the sulfhydryl 
group of peptide cysteine residue and C\C bond of the maleimide ring of sulfo-GMBS. A 
nonpolar homopeptide was used as control for aspecific interactions with siRNA. The molar 
ratio peptide/siRNA* used in the functionalization procedure has been established by a gel 
shift assay, highlighting the complex electrostatic interaction as function of the positive 
peptide (NH3
+
)/negative RNA (PO4
−
) charge ratios. siRNA (50 pmol) was mixed with 
arginine peptides at various N/P ratios (0–2). The results showed that the electrophoretic 
migration of RNA was retarded with an increasing ratio of peptide/RNA (Figure 5.2A). The 
intensity of the siRNA band decreased as the N/P ratio increased. No siRNA band was 
observed at the N/P ratio of 20. This absence of migration was probably due to the complete 
neutralization of nucleic acid charge by the arginine peptide and/or formation of a large 
complex between the arginine and siRNA. These results strongly suggest that an arginine 
peptide made of 8 residues could be sufficient to form a complex with a siRNA. In addition, 
the capability of the peptide/siRNA complex to protect siRNA from nuclease degradation was 
investigated. For this purpose, human pancreatic ribonuclease (HP-RNase) able to degrade 
double-strand RNA, was used [9]. 
 
 
Fig. 5.2. (A) Poly D-Arg peptide (N) and siRNA (P) were incubated at different molar ratios 
(range 0–20, as indicated above each lane) and the formed complex was analyzed by gel shift. 
(B) Effect of HP-RNase on siRNA degradation; siRNA alone (lane a), siRNA incubated with 
HP-RNase in absence (lane b) or in the presence (lane c) of poly D-Arg peptide. 
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As shown in Figure 5.2 (B), siRNA was rapidly degraded by HP-RNase (lane b), while, when 
preincubated with peptide before adding RNase, no significant degradation was observed 
(lane c). The results confirmed that a poly D-Arg peptide strongly interacts with siRNA 
forming a highly stable complex [9, 10]. Furthermore, the formation of the peptide/siRNA 
complex improved the siRNA stability protecting it from nuclease degradation [11]. 
The capability of loaded DNPs to release siRNA* in solution was evaluated by fluorescence 
intensity measurement of both supernatant and DNPs as function of time (Figure 5.3). siRNA 
was released into supernatant in two phases: an initial phase of 12 h (burst release), followed 
by slow and sustained release phase over 48–72 h. The fluorescence profile of DNPs showed 
an opposite trend. The slow siRNA release observed was probably due to the progressive 
weakening of the electrostatic interactions between peptide and nucleic acid. 
 
 
Fig. 5.3. Fluorescent labelled siRNA bound to DNPs (DNPs–siRNA*) was incubated in 
20mM Tris–HCl and 20mMNaCl, pH 7.5 at 37 °C and at time intervals the fluorescence 
intensity was measured in the sample supernatant (●) and diatomite (■). 
5.1.2 siRNA-modified DNPs: cellular internalization and gene silencing 
H1355 cells were incubated with siRNA* modified DNPs (DNPs–siRNA*) to evaluate the 
siRNA uptake and cellular internalization. Figure 5.4 shows a representative confocal 
microscopy image of cells treated with DNPs–siRNA* compared to untreated cells as control. 
Fluorescence images show cell nuclei stained with Hoechst 33342 (blue) and cell membranes 
with WGA-Alexa Fluor 488 (green). Confocal microscopy analysis was performed after 
treatment with DNPs–siRNA* for 24 h. In Figure 5.4 the presence of siRNA (labelled with 
Dy547, red) into the H1355 cells treated with DNPs–siRNA* is evident. Merging the image 
shows that siRNA molecules are localized in the cytoplasm. Red fluorescence (siRNA*) was 
found as both spots and diffuse signal [12–14].  
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Fig. 5.4. Confocal microscopy of cells treated with siRNA*modified DNPs. Scale bar 
corresponds to 20 μm. 
 
 
 
Fig. 5.5. (A) Immunoblotting analysis of GAPDH (upper gel) and of β-tubulin (lower gel) of 
protein expression in DNPs–siRNA treated cells. Lanes: 1) control cells; 2)DNPs–GAPDH–
siRNA; 3) DNPs–SCR–siRNA. (B) Densitometric intensity band ratio of GAPDH and β-
tubulin used as internal control. The intensities of the bands were expressed in arbitrary 
units.(C) Immunoblotting analysis of GAPDH (upper gel) and of β-tubulin (lower gel) protein 
expression in lipofectamine-siRNA transfected cells. Lanes: 1) control cells; 2) GAPDH–
siRNA; and 3) SCR–siRNA. (D) Densitometric intensity band ratio of GAPDH and β-tubulin 
used as internal control. The intensities of bands were expressed in arbitrary units. Each 
measurement and Western blot was carried out in triplicate. Error bars indicate the maximum 
deviation from the mean value of two independent experiments. 
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The efficiency of DNPs–siRNA* internalization was quantified by fluorescence microscopy: 
counting the number of red fluorescent cells and the total number of cells (determined in 
bright field), a ratio of about 75% was calculated. Finally, the ability of the DNPs–siRNA 
complexes to silence in H1355 cells targeted mRNA was investigated by Western blot 
analysis. In particular, a siRNA against glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and a scramble siRNA as control were used. Moreover, to compare the efficiency 
of the DNPs–siRNA delivery system with that of other system, the commercially available 
Lipofectamine 2000 transfection reagent was used. The obtained results are reported in Figure 
5.5. Compared to untreated cells, GAPDH protein expression level after incubation of the 
cells with DNPs–siRNA complexes at 37 °C for 48 h was reduced (Panel A, upper gel) of 
about 22% (lane 2) as evaluated from the densitometric intensity of the bands (Panel B). Cells 
incubated with DNPs–SCR–siRNA (lane 3) showed instead almost identical protein 
expression level as control (lane 1), thus demonstrating the selective inhibition by siRNA. 
Panels C and D report the expression level and the densitometric analysis, respectively, of 
cells transfected with lipofectamine. In this case, GAPDH protein expression level (lane 2) 
was down-regulated of about 20%. Even if the delivery efficiency of DNPs and lipofectamine 
2000 was similar, the use of diatomite as nanocarrier is more suitable for medical applications 
since it allows: (1) slow release of the loaded drug; (2) loading with one or more different 
molecules (e.g., siRNA + drug); (3) biocompatibility of the system; and (4) selective targeted 
functionalization to improve the delivery of anti-tumoral molecules to a specific cell 
population. The results obtained endorse DNPs as innovative nanocarriers for siRNA 
transport in cancer cells highlighted the non-toxic nature of the material, the effective cellular 
uptake and gene silencing in cancer cells.  
5.2 Enhancement of DNPs stability, biocompatibility and cellular internalization in 
cancer cells 
The main peculiarities of NPs as drug delivery systems are their low toxicity, high stability, 
biocompatibility, and suitability for cellular uptake. Several reports in the literature have 
demonstrated the enormous advantages arising from using polymers in the design of drug 
nanocarriers, such as the reduction of non-specific aggregation in aqueous medium and the 
increase of NPs stability, biocompatibility, drug loading, and cellular internalization [12–14]. 
The enhancement of the NPs’ cellular uptake is one of the key issues in drug delivery; 
however, the cell membranes prevent drug carriers from entering the cells, unless an active 
transport mechanism is involved [15]. An efficient approach to deliver NPs or molecules 
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within the cells is to bind them to peptides that can cross the cellular membranes, enhancing 
their translocation inside the cells. Cell penetrating peptide (CPP) bioconjugation has been 
proved as a valid strategy to improve the intracellular drug delivery of conventional small 
drug molecules, NPs or oligonucleotide, and peptide-based therapeutics, increasing their 
systemic diffusion due to the CPP’s property to overcome the lipophilic barrier of the cellular 
membranes and deliver these therapeutics inside the cells [16, 17]. Herein, for the first time, a 
valid biofunctionalization based on PEGylation and CPP biocongiugation able to improve the 
aqueous stability of DNPs, enhancing their hemocompatibility, minimizing their cytotoxicity, 
and increasing the solubility of a poorly water-soluble anticancer model drug, sorafenib was 
demonstrated. In order to obtain an effective DNPs PEGylation, the bare NPs were 
hydroxylated by Piranha solution, thus increasing the reactivity of their silica surface, by 
introduction –OH groups. Covalent bond between PEG and DNPs requires the DNPs 
salinization using an APTES solution, which introduces the highly reactive amino groups (–
NH2) onto the NPs surface (DNPs-APT) that can be covalent conjugated with the carboxyl 
groups of PEG molecules using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/NHS 
chemistry (Scheme 5.1, I) [18, 19]. Without this double-step chemical surface treatment, it 
would not be possible to obtain stable covalently-bonded PEG or CPP DNPs complexes. Due 
to the polymer solubility in water and in a wide variety of organic solvents used during the 
NPs modification, it is crucial that the polymer is covalently bound onto the NPs’ surface in 
order to avoid its untimely detachment [18, 19] To improve the DNPs’ cellular uptake, the 
free amino groups of DNPs-APT-PEG were further chemically conjugated with the carboxyl 
groups of CPP-peptide, known to highly facilitate the delivery of cargos (e.g., peptides, 
proteins, genes, and even nanoparticles) across the cell membrane, by EDC/NHS chemistry 
(Scheme 5.1, II) [20]. 
 
Scheme 1. Schematic representation of the DNPs functionalization. Reaction I, the 
PEGylation of DNPs-APT (I) via EDC/NHS, under stirring ON at RT. Reaction II,CPP-
peptide bioconjugation of DNPs-APT-PEG via EDC/NHS, under stirring ON at RT.  
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The DNPs were characterized before and after the surface modification by DLS, analysing the 
hydrodynamic diameter, the PDI, and the surface charge ζ-potential of the particles. An 
increase of the particles’ size from 317  8 nm to 364  3 nm (DNPs-APT) after the APTES 
solution treatment was observed, confirming the successful of silanization process. A 
progressive decrease of the nano-aggregates’ size was observed after PEGylation and CPP 
bioconjugation. The NPs’ size decreased from 364  3 nm (DNPs-APT) to 346  4 nm after 
PEGylation (DNPs-APT-PEG), and to 340  8 nm after CPP-conjugation (DNPs-APT-PEG-
CPP). This result is due to an increase of the DNPs’ surface repulsion forces of the modified 
surface (DNPs-bare, 19.2  2.0 mV; DNPs-APT, +19.8  3.0 mV; DNPs-APT-PEG, +35.6  
1.5 mV; DNPs-APT-PEG-CPP, +40  2 mV), which can be attributed to the positive charge of 
PEG and CPP-peptide onto the NPs’ surface. As a result, the DNPs stability was improved in 
aqueous solution and a decrease in the PDI of the NPs was also observed (data not shown). 
The chemical silanization, PEGylation and CPP-conjugation of DNPs were further analysed 
by ATRFTIR spectroscopy. Figure 5.6 shows the progressive change of DNPs FTIR spectra 
after each modification step. All spectra of DNPs showed an intense band at 1100 cm
-1
 that 
corresponds to Si-O-Si bonds, because silica is the main constituent of the diatomite frustules.  
 
 
Fig. 5.6. ATRFTIR spectra of modified-DNPs. DNPs were characterized before the 
biofunctionalization (black line), after the silanization process (red line), after the PEGylation 
(blue line), and also after the CPP-peptide bioconjugation (green line). The a indicates CHx 
stretching vibration, b the bending mode of the free NH2, c the C–N stretching, d the C–H 
bending vibrations, and f-I and f-II N–H bending vibration and the C–N stretching vibration, 
respectively. 
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After the silanization process, the DNPs-APT displayed the typical bands of APTES 
corresponded to the CHx stretching at 29412570 cm
-1
, the bending mode of the free NH2 at  
16301470 cm-1, and the C-N stretching at 1385 cm-1[21, 22]. After the PEGylation, the 
DNPs-APT-PEG showed the stretching bands of CHx at 29602849 cm
-1
, the C-H bending 
vibrations at 21601722 cm-1, the amide I band at 1640 cm-1 associated to the C=O stretching 
vibration, the amide II resulted from the N–H bending vibration, and the C–N stretching 
vibration at 1580 and 1360 cm
-1
, respectively, thus confirming the covalent binding of the 
PEG molecules onto the NPs’ surface [22]. After incubation with the CPP-peptide, the DNPs-
APT-PEG-CPP displayed a band at 29842881 cm-1corresponding to the CHx stretching, and 
at 1930 cm
-1
assigned to the C–N stretching of amide II, confirming the successful CPP-
peptide bioconjugation to the surface of the NPs [23, 24]. 
5.2.1 Hemocompatibility test of modified-DNPs 
The hemotoxicity, based on the %-lysed red blood cells (RBCs), is an important preclinical 
study to evaluate the level of the NPs hemocompatibility, in order to avoid serious risks to 
human health (e.g., after intravenous injection of NPs), considering that the erythrocytes 
constitute a large volume portion of the blood. Moreover, if NPs induce hemolysis, there is a 
higher risk that blood constituents can react immunologically to inactivate the NPs, and thus, 
affecting their function and increasing their elimination by macrophages [25, 26].  
In order to evaluate the impact of the modified-DNPs on RBCs, the hemocompatibility and 
the morphological studies of RBCs were determined after exposure to the modified-DNPs at 
increasing incubation times (1, 4, 24, and 48 h) and NP concentrations (25, 50, 100, and 200 
µg/mL) [27]. The %-hemolysis determined by spectrophotometric analysis of the supernatants 
after 48 h incubation at the maximum concentration of modified-DNPs (200 µg/mL) was 34 % 
for DNP-APT, 7 % for DNP-PEG, and 1.3 % for CPP-DNP. This result clearly demonstrated 
that the biofunctionalization of the NPs improved the DNPs hemocompatibility (Figure 5.7).  
The morphological changes of the RBCs after exposure to the modified-DNPs (200 µg/mL for 
4 h, at RT) were examined by SEM characterization. The RBCs, in the presence of DNP-APT, 
completely altered their morphology, changing from the biconcave-like disks to shrinked 
shape, with consequent hemolysis (Figure 5.8). The DNPs-APT hemotoxicity is attributed to 
the free positive amine groups existing on the surface of the NPs, which strongly interact with 
the negative charge surface of the RBCs, resulting in hemolysis and changing of the cell’s 
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shape. In the case of PEGylated particles, no severe change was observed in the RBCs 
morphology, but the cell membrane locally wrapped around with the appearance of small 
holes without significant hemolysis. The relevant decrease of the DNPs-APT hemotoxicity 
after PEGylation is due to the improved biocompatibility of the NPs as a result of the 
presence of PEG on their surface, which is known to be relatively non-cytotoxic, non-
immunogenic, non-antigenic, and decrease the protein interaction [28, 29]. In the case of 
DNPs-APT-PEG-CPP, there was not relevant change observed in the RBCs’ morphology due 
to the low cytotoxicity of CPP-peptide, which improved the DNPs biocompatibility [30]. 
Therefore, both the amino function and also the charge density (the number and special 
arrangements of the cationic residues) is an important factor for toxicity [31]. 
 
 
Fig. 5.7. Hemocompatibility of the modified-DNPs. Hemotoxicity of APT-, PEG- and CPP- 
modified DNPs incubated for 48 h at different concentrations (25, 50, 100, and 200 µg/mL) 
with RBCs, estimated by spectrophotometric methods (577 nm) to analyse the amount of 
lysed-hemoglobin in the supernatants. The insert Figures show the magnifications of the 
graphs. Statistical analysis was made by ANOVA. The level of significance from negative 
control was set as probabilities of *p < 0.05**p < 0.01 and ***p < 0.001. Error bars 
represent s.d. (n = 3). 
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A three-point attachment are necessary for eliciting a biological response on cell membranes 
and the activity of a molecule decreases when the space between reactive amino groups 
increases in the primary structure [31]. The arrangement of cationic charges on the molecules 
structure determines the accessibility of their charges to the cell surface [30]. This study 
confirms these observations, where APTES showed more toxicity than PEG and CPP, due to 
the simple molecule structure formed by short amino-alkyl chains of APTES, and thus, more 
accessibility of amino groups to interact with the cells. As shown in Figure 5.8, very small 
amounts of APT- and PEG-modified DNPs (indicated by white arrows) were adsorbed onto 
the RBCs’ surface, while a considerable amount was observed for CPP-DNPs, thus this 
biofunctionalization significantly improved the DNPscells membrane interactions. 
 
 
 
Fig. 5.8. SEM pictures of the RBCs morphological modification after the exposure to the 
modified-DNPs. The modified DNPs (100 µg/mL) were incubated with RBCs for 4 h at RT. 
The DNPs-APT showed the higher toxicity than the PEG and CPP-modified DNPs, resulting 
in severe morphological changes of cell. The CPP-bioconjugation improved significantly the 
DNPscells membrane interactions, as indicated by white arrows. Scale bars are 3 µm. 
 
5.2.2 In vitro cell viability assay 
The biocompatibility and toxicity of the DNPs were assessed by measuring the adenosine 
triphosphate (ATP) activity of the MCF-7 and MDA-MB-231 cells exposed to the bare and 
modified-DNPs, after 6 and 24 h of incubation time at different NP concentrations (25, 50, 
100, and 200 µg/mL). The exposure of MCF-7 and MDA-MB 231 cells to increasing 
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concentrations of bare diatomite NPs within 24 h of incubation time induced very low toxicity, 
demonstrating their potential applicability as nanovectors in nanomedicine (data not shown). 
The modified-NPs showed the same degree of cytotoxicity on both cell lines, as shown in 
Figure 5.9. The DNPs-APT showed significant cytotoxic activity after 6 h of incubation and at 
lower concentration (25 µg/mL). By increasing the incubation time and the NPs concentration, 
in an increased cytotoxicity of the NPs, was observed. After PEGylation and CPP-
bioconjugation to the DNPs-APT, the cytotoxicity was significantly decreased after 24 h of 
incubation compared to the negative control (HBSSHEPES, pH 7.4). In addition, no 
significant dependency on the exposure time and NPs concentration was observed on the 
cytotoxicity of the PEGylated and CPP-biofunctionalized NPs. The toxicity of DNPs-APT can 
be attributed to the positive charge of free amino groups of APTES, as discussed previously. 
These results are in agreement with the hemotoxicity data, confirming an increase in the 
DNPs’ biocompatibility after the functionalization with PEG and biofunctionalization with the 
CPP-peptide. These results further suggest that DNPs-APT-PEG-CPP could be used as 
nanocarrier for long incubation times and high concentrations. 
 
 
Fig. 5.9. Cell viability of MCF-7 (a and b) and MDA-MB-231 (c and d) cells after exposure to 
the modified-DNPs at different concentrations. Statistical analysis was made by ANOVA 
comparing all data sets to the negative control HBSS (pH 7.4). The HBSS–HEPES (pH 7.4) 
and Triton X-100 were used as negative and positive controls, respectively. The level of 
significance was set at probabilities of 
*
p< 0.05, 
**
p< 0.01, and ***p< 0.001. Error bars 
represent s.d. (n = 3). 
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5.2.3 Cellular uptake of the modified-DNPs 
Another key requirement of the nanocarriers for drug delivery is the cellular internalization 
into cancer cells without damaging the cellular integrity of healthy cells; therefore, the surface 
chemistry of the NPs has a significant impact on the NPs performance in biomedical 
applications. Several peptides, capable of translocation in cellular membranes, have been used 
to improve the NPs’ cellular uptake [32, 33]. The CPP-peptide used, consists of a short basic 
amino acid sequence with a net positive charge sequence and has the ability of facilitating the 
delivery into the cells of various molecular cargos, such as oligonucleotides, small molecules, 
siRNA, NPs, peptides and proteins [34]. The cellular uptake was evaluated by confocal 
fluorescence microscopy after DNPs and cellular membrane labelling with Alexa Fluor-488
®
 
and CellMask™ Deep Red, respectively. Initially, the cellular internalization of modified-
DNPs was evaluated on MCF-7 at two different incubation times (6 and 12 h) in order to 
determine the time required for a satisfactory uptake. The best incubation time, regardless of 
the modified-DNPs type, was 12 h; while the NPs were localized prevalently in the cellular 
membranes after 6 h. In both the cell lines, an increase in the NPs’ cellular uptake after CPP-
bioconjugation was observed, as shown in Figure 5.10. The merge images of the CPP 
modified-DNPs showed a yellow colour, resulting from the co-localization of the green 
labelled-DNPs and red colour of cell membranes, which indicates the presence of the NPs 
inside the cells. In the case of the APTES-modified NPs, more cellular uptake was observed 
compared to the NPs functionalized with PEG, due to the presence of the free amino groups 
of APTES. The cellular uptake was also evaluated by TEM imaging of both cancer cells after 
12 h of incubation with the modified-DNPs (50 µg/mL), confirming the results obtained for 
the confocal fluorescence microscopy studies. In Figure 5.11, the APTES-modified DNPs 
were mainly localized in the proximity of the cell membrane, while in the case of the DNPs-
APT-PEG, no significant cellular uptake was observed. For the CPP-modified NPs, a 
considerable amount of DNPs was internalized into the cells with a homogeneous distribution 
into the cytoplasm and very close to the nucleus. All these results confirmed that the CPP 
bioconjugation is a valid functionalization strategy to increase the cell penetration of 
diatomite NPs. The benefit of CPP on the surface of the NPs is the ability to translocate into 
the intracellular compartment without causing any cell membrane damage, resulting in low 
cytotoxicity and high uptake efficiency [3537]. 
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Fig. 5.10. Confocal fluorescence microscopy of MCF-7 (a) andMDA-MB-231 (b) cells treated 
with APT-, APT-PEG, APT-PEG-CPP modified-DNPs for 12h at 37°C.  
 
 
 
Fig. 5.11. TEM images of MCF-7 (a) and MDA-MB-231 (b) cells treated with 50 µg/mL of 
DNPs-APT, DNPs-APT-PEG, and DNPs-APT-PEG-CPP for 12h at 37°C.  
5.2.4 Drug loading and release studies 
The ultimate goal of targeted drug delivery is to deliver the administered drug to the target, 
while eliminating or minimizing the accumulation of the drug at any non-target site with 
minimal side effects [38]. In this context, the poorly water-soluble anticancer drug, sorafenib 
(SFN), was used as a model drug to investigate the loading efficacy in the modified-DNPs 
and the release profiles in aqueous buffer solutions at pH 7.4 and 5.5, mimicking the 
physiological and intratumoral pH, respectively. The multikinase inhibitor SFN, is considered 
a promising targeted protein kinase agent for the treatment of a broad range of cancers due to 
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Fig. 5.12. Drug release profiles of the SFN-loaded DNPs in HBSS-HEPES + 10 % FBS at pH 
7.4 (a) and pH 5.5 (b) at 37 °C. Values represent the mean ± s.d. (n = 3). 
 
its significant both in vitro and in vivo antitumor activity, resulting in the tumor growth 
inhibition and disruption of tumor microvasculature through antiproliferative, antiangiogenic, 
and/or proapoptotic effects [39, 40]. Firstly, the loading degree of SFN in APT-, PEG-, CPP-
modified DNPs was evaluated in order to determine the influence of the surface 
biofunctionalization on the drug loading. The loading degree of SFN was 10.4 ± 1.1% in the 
DNPs-APT, 22 ± 2 % in the DNPs-APT-PEG, and 17 ± 2% in the DNPs-APT-PEG-CPP. The 
surface biofunctionalization improved the drug loading, entrapping higher amounts of drug 
into the modified DNPs than in APTES alone. In the case of PEG-modified DNPs, an higher 
amount of the drug was loaded than in DNPs-APT, probably due to weak interactions (e.g., 
Van der Waals forces) between PEG and the SFN [43]. The CPP-conjugation step, even if it 
requires overnight bioconjugation time and several washes after the reaction, causes only a 
very small decrease in the drug loading, possibly due to some removal of the adsorbed PEG 
molecules that are not covalently bound to the NPs surface. The release profiles of SFN were 
assessed in HBSSHEPES + 10% FBS solution at pH 7.4 and 5.5 (Figure 5.12). The 
dissolution of pure SFN within 24 h (data not shown) in the aqueous solution (pH 7.4 and 5.5) 
was negligible. In the case of SFN-loaded in APT- and CPP-modified DNPs, the drug release 
in both buffer solutions (pH 7.4 and 5.5) was gradual and constant within 4 h. SFN is 
characterized by its very poor water solubility, and the results show that the surface 
modification of DNPs improved the solubility of drug in aqueous solution, but the 
functionalization of DNPs with CPP did not significantly influence the release profile of the 
drug loaded. However, in view of DNPs use for in vivo drug release and anticancer studies, it 
should be recommended to use CPP-modified DNPs for the remarkable results of stability, 
biocompatibility and cellular uptake obtained here. 
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6 EVALUATION OF DIATOMITE NANOPARTICLES TOXICITY IN 
LIVING ORGANISM HYDRA 
 
The use of nanoparticles in experimental and clinical settings has exponentially revolutionised 
medical imaging, diagnostics, therapeutics as well as carry out biological processes [1–3]. 
This highlights the need to consider not only the usefulness of NPs but also the potentially 
unpredictable and adverse consequences in humans [4]. NPs toxicity refers to the ability of 
the particles to adversely affect the normal physiology as well as to directly interrupt the 
normal structure of organs and tissues of humans and animals. It is widely accepted that 
toxicity depends on physiochemical parameters such as particle size, shape, surface charge 
and chemistry, composition, and subsequent NPs stability [5–8]. In vitro toxicity testing is the 
most common scientific analysis used to determine the effects of NPs toxicity on cultured 
mammalian cells. However, the successful of in vitro assays is not predictive for promising in 
vivo results; for this reason the in vivo evaluation of NPs toxicity is a crucial issue to develop 
nanodevices useful for biomedical applications. In this context, Hydra vulgaris (Cnidaria, 
Hydrozoa) was used as preliminary in vivo model to evaluate diatomite NPs toxicity, in order 
to compare the in vitro results with in vivo ones. 
6.1 Hydra Vulgaris as in vivo model for toxicity assessing 
Hydra is one of the simplest multicellular organism at the base of the metazoan evolution 
known, and consists of a tube made up of two connected epithelial cell layers: the outer 
ectoderm and inner endoderm, separated by an acellular mesoglea layer (Figure 6.1) [9]. As 
shown in Figure 6.1 A, at the top end of the tube, there is the hypostome composed by a 
mouth surrounded by 6-8 tentacles that contains the most part of stinging cells (cnidocytes or 
nematocytes) that let Hydra to catch its prey [10]. Hydra column has four distinctive sections: 
the gastric region located between the tentacles and the first (apical) bud; the budding section 
which produces the buds; the peduncle which is located between the lowest bud and basal 
disc and the basal disc which is the foot-like formation [11]. This structural complexity, 
simpler than vertebrates with central nervous system and specialized organs, but more 
complex than cultured cells, makes Hydra comparable to a living tissue whose cells and 
distant regions are physiologically connected. It possess a simple nervous system which 
include a nerve net that stretches throughout the body [12]. Hydra typically reproduces 
asexually resulting in the rapid production of a large number of new organisms that can be 
cultured in a short period of time. Hydra is sensitive to a range of pollutants and has been 
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used as a biological indicator of water pollution [13]. Metal pollutants such as copper, 
cadmium, and zinc have been tested against different Hydra species, and the relative toxicity 
based on the median lethal concentration (LC50) for all species was ranked from copper, the 
most toxic, to cadmium with zinc, the least toxic [13]. Drugs and pharmaceuticals targeted at 
mammalian receptors have also been shown to adversely affect Hydra, showing the feasibility 
to use this aquatic invertebrate to accurately assess the potential toxicological effect of 
pharmaceuticals entered into natural waters through sewage effluent and landfill leakages [14]. 
 
 
Fig. 6.1. Anatomical structure of Hydra vulgaris. The inset shows the bilayer structure 
characterizing the whole body, from the foot to the tentacles, i.e. the ectoderm and endoderm 
layers separated by the mesoglea. The few specialized cell types differentiated by the 
interstitial stem cells are shown (neurons, cnidocyte, gland cells). 
 
Hydra has been used as alternative in vivo model, to study the toxicity of different NPs, as 
well as their uptake and fate [15]. Due to a simple tubular body and being diploblastic, an 
uniformity exposure of the whole animal to any given NPs by simple soaking is allowed [16, 
17]. Several bioassays are available to assess the toxicity of a given substances in terms of 
acute or sub-lethal toxicity. Hydra exposure to different substances may cause (1) alteration of 
morphological traits and developmental programs, (2) alteration of regeneration or pattern 
formation; (3) alteration of population growth rates; measuring Hydra population growth by 
asexual reproduction. Moreover, the toxicity can also be analysed on single cells by 
macerating the hole animal in fixed cell suspension. 
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6.2 Impact of DNPs on Hydra morphology and cellular uptake 
The toxicity of substances in Hydra is conventionally measured in observing changes in the 
animal morphology following Wilby's classification ranging from score 10 (normal, elongated 
tentacles and body), 8 (clubbed or bulbed tentacles), 6 (shortened tentacles), 5 (tulip phase), 2 
(loss of osmoregulation) to score 0 (disintegrated) [18]. Scores 10–6 are reversible, sub-lethal 
indicators while the tulip phase (score 5 and below) is considered irreversible and used as the 
endpoint for lethality (Figure 6.2) [18, 19].  
 
 
Fig. 6.2. Score system to assess toxic effects on Hydra based on Wilby's classification [19]. 
 
Toxicity of diatomite NPs in Hydra was investigated by monitoring changes in morphology 
after exposure to the DNPs at increasing incubation times (24, 48 and 72 h) and NP 
concentrations (0.5 mg/mL, 1 mg/mL, 1.5 mg/mL, 2.5 mg/mL, 3 mg/mL, 3.5 mg/mL, 4 
mg/mL). Hydra Vulgaris were asexually cultured in physiological solution by the method of 
Loomis and Lenhoff with minor modifications [20]. The animals were kept at 18 °C and fed 
three times per week with freshly hatched Artemia salina nauplii. All animals were starved 24 
h prior to the experiments. For each DNPs concentration twenty polyps were used. Either 
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control or treated animals were placed into plastic multiwells refreshing the medium every 
24 h. The morphophysiological effects of DNPs on Hydra were recorded by microscopic 
examination of each polyp and used to extrapolate the Wilby’s score key. A representative in 
vivo images of morphological characterization of Hydra after exposure to DNPs is reported in 
Figure 6.3. Any change in polyp morphology wasn’t observed after exposure to DNP 
concentrations up 4 mg/mL for 72 h; this result corresponds to score 10 of Wilby’s 
classification. 
 
 
Fig. 6.3. Morphological in vivo analysis of DNPs effects on Hydra morphology.Scale bar 1 
mm. 
 
These data confirm in vitro toxicity results. The transparency of Hydra epithelium makes 
possible to track and localize the fluorescent nanoparticles in the animal body [17]. The 
internalization of DNPs in Hydra was evaluated by in vivo fluorescence microscopy analysis, 
after labelling DNPs by Alexa Fluor-488
®
 (DNPs*). Ten living Hydra were treated with 
DNPs* (3.5 mg/mL) up to 72 h. Bright-field and fluorescence images of Hydra polyps treated 
with DNPs* for 24 (C, D) and 72 h (E, F) are reported in Figure 6.4; Figures 6.4 A and B 
show an untreated animal as control. In all figures, the foot is on the lower part of the panel, 
while a crown of tentacles surrounds the mouth. The image taken after 24 h (D) shows an 
intense fluorescence of DNPs, distributed in the whole body and confined to the outer 
ectoderm. After 72 h (F) of incubation the DNPs were mainly localized in the inner 
endodermal cells, due to inter-epithelial migration of free or cell- containing nanoparticles 
between the two cell layers [19]. These preliminary in vivo results are in agreement with the 
in vitro data, confirming that DNPs could be used as safe and biocompatible nanocarrier for 
long incubation times and high concentrations. 
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Fig. 6.4. In vivo fluorescence imaging of Hydra polyps treated with labelled DNPs (3.5 
mg/mL) for different incubation times. Scale bars 1 mm. The fluorescence pattern appears as 
rather uniform after 24 h of incubation, while at 72 h it appears as granulates covering most 
of body regions. They might represent storage vacuoles, as it has been shown for other 
fluorescent nanoparticles [16, 19]. 
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7 CONCLUSIONS 
 
The development of organic–inorganic hybrids with controlled morphology at the nanometer 
scale, represented a triumphant class of materials for progress of healthcare devices 
technology. Porous silicon is an appealing nanostructured material, largely used in biomedical 
applications, due to the ease of tuning its properties, such as pore morphology, photonic 
properties, biocompatibility, biodegradation and surface chemistry. This PhD thesis work was 
focused on the realization of porous silica based devices, paying particular attention to 
functionalization strategies, in order to obtain advanced systems for biosensing and drug 
delivery applications. Porous silicon structures are widely used by far as optical transducers 
for biosensors development in lot of laboratories, and even commercial applications. 
However, the main drawback of these easy-to-produce and sensitive devices is their low 
chemical stability in aqueous solutions, actually used in biochemical experiments. The 
realization of DNA-PSi devices with great stability, fast response time, high sensitivity and 
specificity was demonstrated in the first part of this PhD thesis work. Two common routes of 
passivation/functionalization by grafting alkylsilanes through the formation of Si–O–Si bonds 
between silanol groups induced on the oxidized PSi surface and hydrolysed organosilane 
molecules of APTES or APDMES was investigated. Both compounds, but with some 
differences, form a thin film on PSi surface, which can effectively protect the porous support 
against corrosion on exposure to aqueous solution. It is well known, that APTES can 
polymerize forming a multi-layered interface, while APDMES cannot do it. Despite this not 
negligible distinction, both silane-modified PSi devices shown good chemical resistance to 
reagents used for in situ synthesis. In particular, APDMES passivation, due to less steric 
hindrance of the pores, resulted in a better oligonucleotide (ON) functionalization quality with 
respect to APTES in case of mesoporous structures. Finally, hybridization to a target sequence 
of oligonucleotide synthetized on APDMES modified porous silica optical structure was 
demonstrated by complementary optical techniques, such as spectroscopic reflectivity and 
fluorescence microscopy. The development of DNA label-free optical biosensors through in 
situ synthesis of a 13-mer polythymine ON strand, deprotection and hybridization with a 
complementary ON, was successfully demonstrated, opening the prospective of PSi solid 
phase ON synthesis without any restriction on the ON sequence, giving more general 
significance to the proposed methodology. Starting from these results, a stable sensitive and 
reversible PSi-aptasensor realized by in situ synthesis for label-free optical detection of 
human thrombin, was developed. Thrombin is an allosteric serine protease with a crucial roles 
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in physiological and pathological coagulation, and also involved in various diseases, such as 
Alzheimer’s disease and cancer. Anti-thrombin aptamer (TBA) was synthetized in silanized 
macroporous PSi structure which, due to an average pore size of about 140 nm allowed a 
correct synthesis of the bioprobe with proper yield. In order to enable thrombin biomolecular 
recognition, TBA was deprotected by dry ammonia in methanol thus preserving the structural 
integrity of the PSi matrix. The sensing mechanism based on high affinity between TBA 
aptamer and α-thrombin was monitored by label-free method based on spectroscopic 
reflectometry, showing a limit of detection of 4.0 ± 0.9 nM and high sensitivity for the 
thrombin, comparable to the other DNA devices realized using more complicated and 
expensive technologies. In addition, the reversibility of PSi-aptasensor was also 
demonstrated, proving the reusability of biosensor for subsequent sensing event, through its 
simple washing with heated water at melting temperature (53 °C). The encouraging results 
obtained suggest the potentiality to develop a wide range of stable and high sensitive PSi 
aptasensors by in situ synthesis for human disease early diagnosis. Porous silicon is also one 
of the most commonly used material for the development of drug-delivery systems. In recent 
years, there was a need to explore alternative porous silica materials for drug-delivery 
applications in order to address some disadvantages of the synthetic porous materials, finding 
in diatomite a great surrogate. Diatomite is a natural nanostructured silica material of 
sedimentary origin formed by fragments of diatom skeletons, characterized by chemical 
inertness, thermal stability, high surface area, non-toxicity and biocompatibility. Although, its 
peculiar properties, diatomite has been explored for a large number of applications ranging 
from photonics to water filtration, but it is underestimated in nanomedicine. In the second part 
of this PhD thesis work, diatom frustules reduced to nanoparticles (NPs) were explored, for 
the first time, as potential nanocarriers for drug delivery applications. A procedure based on 
mechanical and chemical treatments for preparing diatomite NPs (DNPs) with an average size 
of 300 nm and to make them safer for medical applications, was developed. The nanosize of 
the DNPs, obtained after the processing of the raw diatomite powder was evaluated by 
scanning electron microscopy (SEM), transmission electron microscopy (TEM), and dynamic 
light scattering (DLS) analysis. The variation in the chemical composition of diatomite 
powder before and after purification treatment was evaluated by photoluminescence (PL), 
Fourier transform infrared spectroscopy (FTIR) and energy dispersive X-ray spectroscopy 
(EDS) analyses, confirming the improvement of the silica nanopowder quality due the 
removal of impurities. Preliminary tests of cytotoxicity and cellular uptake demonstrated the 
biocompatibility of the DNPs and their capability to penetrate inside cancer cells. Since the 
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silica surface of diatomite is covered by silanol (SiOH) groups, it can be easily modified with 
functional reactive groups (−NH2, −COOH, −SH, and −CHO) for the conjugation of 
biomolecules in order to prepare advanced devices. Two different functionalization 
approaches based on covalent bond for bioengineered DNPs fabrication were developed, in 
order to transport therapeutic molecules (smoll interfering RNA (siRNA) and poorly water-
soluble anticancer drug sorafenib) into cancer cells. The first functionalization process based 
on covalent bond between DNPs’ surface and siRNA-peptide complex, demonstrated an 
effective uptake of the engineered siRNA nanovectors into human epidermoid carcinoma 
cells. An enhancement of gene silencing in cancer cells due to siRNA delivered by DNPs was 
also demonstrated. In the second functionalization approach, a dual-biofunctionalization 
based on covalent conjugation of polyethylene glycol (PEG) and cell penetrating peptide 
(CPP) onto the NPs’ surface, was developed. An improvement of the DNPs’ physicochemical 
properties, biocompatibility, cellular uptake and sorafenib drug release in aqueous solution, 
was demonstrated. After these positive in vitro results, Hydra vulgaris was used as simple 
model for preliminary in vivo studies of DNPs toxicity and cellular uptake, confirming the 
safety and the potentiality of diatomite NPs as new nanocarriers. The interesting experimental 
results reported in this PhD work demonstrate the potentiality of synthetic and natural porous 
silica as versatile material for the realization of healthcare smart systems.  
